Processing math: 62%
Research article Special Issues

PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma


  • Received: 30 July 2021 Accepted: 27 September 2021 Published: 09 November 2021
  • Plasmacytoma variant translocation 1 (PVT1) is involved in multiple signaling pathways and plays an important regulatory role in a variety of malignant tumors. However, its role in the prognosis and immune invasion of bladder urothelial carcinoma (BLCA) remains unclear. This study investigated the expression of PVT1 in tumor tissue and its relationship with immune invasion, and determined its prognostic role in patients with BLCA. Patients were identified from the cancer genome atlas (TCGA). The enrichment pathway and function of PVT1 were explained by gene ontology (GO) term analysis, gene set enrichment analysis (GSEA) and single-sample gene set enrichment analysis (ssGSEA), and the degree of immune cell infiltration was quantified. Kaplan–Meier analysis and Cox regression were used to analyze the correlation between PVT1 and survival rate. PVT1-high BLCA patients had a lower 10-year disease-specific survival (DSS P < 0.05) and overall survival (OS P < 0.05). Multivariate Cox regression analysis showed that PVT1 (high vs. low) (P = 0.004) was an independent prognostic factor. A nomogram was used to predict the effect of PVT1 on the prognosis. PVT1 plays an important role in the progression and prognosis of BLCA and can be used as a medium biomarker to predict survival after cystectomy.

    Citation: Peiyuan Li, Gangjie Qiao, Jian Lu, Wenbin Ji, Chao Gao, Feng Qi. PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma[J]. Mathematical Biosciences and Engineering, 2022, 19(1): 169-190. doi: 10.3934/mbe.2022009

    Related Papers:

    [1] Wael S. Abu El Azm, Ramy Aldallal, Hassan M. Aljohani, Said G. Nassr . Estimations of competing lifetime data from inverse Weibull distribution under adaptive progressively hybrid censored. Mathematical Biosciences and Engineering, 2022, 19(6): 6252-6275. doi: 10.3934/mbe.2022292
    [2] Walid Emam, Ghadah Alomani . Predictive modeling of reliability engineering data using a new version of the flexible Weibull model. Mathematical Biosciences and Engineering, 2023, 20(6): 9948-9964. doi: 10.3934/mbe.2023436
    [3] Walid Emam, Khalaf S. Sultan . Bayesian and maximum likelihood estimations of the Dagum parameters under combined-unified hybrid censoring. Mathematical Biosciences and Engineering, 2021, 18(3): 2930-2951. doi: 10.3934/mbe.2021148
    [4] Manal M. Yousef, Rehab Alsultan, Said G. Nassr . Parametric inference on partially accelerated life testing for the inverted Kumaraswamy distribution based on Type-II progressive censoring data. Mathematical Biosciences and Engineering, 2023, 20(2): 1674-1694. doi: 10.3934/mbe.2023076
    [5] M. Nagy, M. H. Abu-Moussa, Adel Fahad Alrasheedi, A. Rabie . Expected Bayesian estimation for exponential model based on simple step stress with Type-I hybrid censored data. Mathematical Biosciences and Engineering, 2022, 19(10): 9773-9791. doi: 10.3934/mbe.2022455
    [6] Said G. Nassr, Amal S. Hassan, Rehab Alsultan, Ahmed R. El-Saeed . Acceptance sampling plans for the three-parameter inverted Topp–Leone model. Mathematical Biosciences and Engineering, 2022, 19(12): 13628-13659. doi: 10.3934/mbe.2022636
    [7] M. E. Bakr, Abdulhakim A. Al-Babtain, Zafar Mahmood, R. A. Aldallal, Saima Khan Khosa, M. M. Abd El-Raouf, Eslam Hussam, Ahmed M. Gemeay . Statistical modelling for a new family of generalized distributions with real data applications. Mathematical Biosciences and Engineering, 2022, 19(9): 8705-8740. doi: 10.3934/mbe.2022404
    [8] Amal S. Hassan, Najwan Alsadat, Christophe Chesneau, Ahmed W. Shawki . A novel weighted family of probability distributions with applications to world natural gas, oil, and gold reserves. Mathematical Biosciences and Engineering, 2023, 20(11): 19871-19911. doi: 10.3934/mbe.2023880
    [9] M. G. M. Ghazal, H. M. M. Radwan . A reduced distribution of the modified Weibull distribution and its applications to medical and engineering data. Mathematical Biosciences and Engineering, 2022, 19(12): 13193-13213. doi: 10.3934/mbe.2022617
    [10] Hatim Solayman Migdadi, Nesreen M. Al-Olaimat, Omar Meqdadi . Inference and optimal design for the k-level step-stress accelerated life test based on progressive Type-I interval censored power Rayleigh data. Mathematical Biosciences and Engineering, 2023, 20(12): 21407-21431. doi: 10.3934/mbe.2023947
  • Plasmacytoma variant translocation 1 (PVT1) is involved in multiple signaling pathways and plays an important regulatory role in a variety of malignant tumors. However, its role in the prognosis and immune invasion of bladder urothelial carcinoma (BLCA) remains unclear. This study investigated the expression of PVT1 in tumor tissue and its relationship with immune invasion, and determined its prognostic role in patients with BLCA. Patients were identified from the cancer genome atlas (TCGA). The enrichment pathway and function of PVT1 were explained by gene ontology (GO) term analysis, gene set enrichment analysis (GSEA) and single-sample gene set enrichment analysis (ssGSEA), and the degree of immune cell infiltration was quantified. Kaplan–Meier analysis and Cox regression were used to analyze the correlation between PVT1 and survival rate. PVT1-high BLCA patients had a lower 10-year disease-specific survival (DSS P < 0.05) and overall survival (OS P < 0.05). Multivariate Cox regression analysis showed that PVT1 (high vs. low) (P = 0.004) was an independent prognostic factor. A nomogram was used to predict the effect of PVT1 on the prognosis. PVT1 plays an important role in the progression and prognosis of BLCA and can be used as a medium biomarker to predict survival after cystectomy.



    In several lifetime tests, including, industrial, lifetime and clinical applications, progressive censoring is very useful. Progressive censoring permits the removal of the experimental units surviving until the test finishes. Let an experiment of experiment with n independent units in which it is not desirable to detect all failure times under the cost and time limitations, so only part of failures of the units are observed and the other part are removed from the experiment, such a sample is called a censored sample. Assume that one of the units was broken by accident after the test began, but before all of the units had burned out. If the experiment is still ongoing, this unit must be removed from the life test. The progressive censoring scheme gives a methodology for analyzing this type of data in this case. Some of the most important works on this subject are Balakrishnan and Aggarwala [1], Balakrishnan [2], and Cramer and Iliopoulos [3].

    The experimentation time can be very long if the units are very reliable, which is a disadvantage of progressive Type-II censored schemes. Kundu and Joarder [4] and Childs et al. [5] address this problem by proposing a new type of censoring in which the stopping time of the experiment is minimum value of {Xm:m:n,T}, where the time T is fixed time before the start of the test. This type of censored sampling is called a progressive hybrid censoring sample (PHCS). The total time of the experiment under a PHCS will not exceed T. Several authors have studied PHCSs. See, for example, Panahi in [6], Alshenawy et al. in [7], Hemmati and Khorram in [8], and Lin and Huang in [9].

    However, the weakness of a PHCS is that it cannot be implemented when a few failures can be detected before time T. For this reason, Cho et al. [10] proposed a general type of censoring, called a generalized Type-I PHCS, in which a smaller number of failures is predetermined. A lifetime test experiment would save the time and costs of failures using this censoring scheme. Moreover, the estimates of the statistical efficiency are improved by the experiment having more failures. In the following section, the generalized Type-I PHCS and its advantages are explained. For recent work on this topic, see, for example, Moihe El-Din et al. [11], Mohie El-Din et al. [12], and Nagy et al. [13].

    The Weibull distribution is one of the most important in reliability and life testing, and it is widely utilized in various domains such as reliability theory and clinical trials. For this reason, we used this distribution to express truly real data. The Weibull distribution has the probability density (PD), cumulative distribution (CD), survival (S), and hazard (H) functions given as follows.

    f(x;λ,μ)=λμxμ1eλxμ,x>0, (1.1)
    F(x;λ,μ)=1eλxμ,x>0,λ>0,μ>0. (1.2)
    S(x;λ,μ)=ˉF(x;λ,μ)=1F(x;λ,μ),  H(x;λ,μ)=λμxμ1,x>0,λ>0,μ>0. (1.3)

    For Bayesian inference on the Weibull distribution, see, for example, Mohie El-Din and Nagy [14], and Lin et al. in [15].

    In this paper, we address the development of point and interval estimation and classical and Bayesian inference for the Weibull distribution based on the generalized Type-I PHCS. The Bayesian estimate for any parameter β, denoted by ˆβBS, in terms of the squared error loss function (SELF), is the expected value of the posterior distribution and given by

    ˆβBS=Eβ|x_[β]. (1.4)

    The LINEX loss function (LLF) can be expressed as follows.

    LBL(ˆβ,β)=exp[υ(ˆββ)]υ(ˆββ)1, υ0, (1.5)

    The Bayesian estimator of β, denoted by ˆβBL under the (LLF), the value ˆβBL that minimizes Eβ|X_[LBL(ˆβ,β)] is given by

    ˆβBL=1υln{Eβ|x_[exp(υβ)]}, (1.6)

    Calabria and Pulcini [16] considered the question of the choice of the value of parameter v.

    The general entropy loss function (GELF) is another widely used asymmetric loss function. It is given by

    LBE(ˆβ,β)(ˆββ)κκln(ˆββ)1. (1.7)

    The Bayesian estimate ˆβBE relative to the GE loss function is given by

    ˆβBE={Eβ|x_[β]κ}1κ. (1.8)

    The remainder of this article is organized as ollows. Section 2 summarizes the model of the generalized Type-I PHCS. Section 3 extracts the maximum likelihood estimates (ML) and the Bayesian estimates for the unknown parameters and SF and HF under three loss functions. Section 4 derives the Bayesian one-sample prediction for all censoring stage failure times of all withdrawn units. In Section 5, we derive the Bayesian prediction for all withdrawn units in the censoring stage {Ri,i=1,...,m}, which is called one-sample Bayesian prediction; and in Section 6, we derive the Bayesian prediction of an unobserved future progressive sample from the same distribution, which is called two-sample Bayesian prediction. In Section 7, simulation studies are conducted to compare the efficiency of the proposed inference techniques. In Section 8, a real-life data set is used to demonstrate the theoretical findings. Finally, the paper is concluded in Section 9.

    Consider lifetime testing in which n equivalent units are tested. The generalized Type-I PHCS is as follows. Let T>0 and k,m{1,2,...,n} be prefixed integers in which k<m with the predetermined censoring scheme R=(R1,R2,...,Rm) satisfying n=m+R1++Rm. When the first failure occurs, R1 of the remaining units are randomly eliminated. When the second failure occurs R2, of the surviving units are eliminated from the experiment. This process repeats until the termination time T=max{Xk:m:n,min{Xm:m:n,T}} is reached, at which moment the reset surviving units are eliminated from the test. The "generalised Type-I PHCS" modifies the PHCS by allowing the experiment to continue beyond T if only a few failures are observed up to T. Ideally, the experimenters would like to observe m failures within this system, but they will observe at least k failures. D is the number of failures observed up to T (see Figure 1).

    Figure 1.  Schematic representation of generalized Type-I progressive hybrid censoring scheme.

    As mentioned earlier, one of observations from the following types is given under the generalized Type-I PHCS:

    1. Suppose the kth failure time occurs after T. Then, experiment is terminated at Xk:m:n and the observations are {X1:m:n<...<Xk:m:n}.

    2. Suppose that T is reached after the kth failure and before the mth failure. In this case, the termination time is T and we observe {X1:m:n<...<Xk:m:n<Xk+1:m:n<...<XD:m:n}.

    3. Suppose that the mth fault was discovered after the kth failure and before T. Then, the termination time is Xm:m:n, and we will find {X1:m:n<...<Xk:m:n<Xk+1:m:n<...<Xm:m:n}.

    The joint PDF based on the generalized Type-I PHCS for all cases is now given by:

    fX_(x_)=[Di=1mj=i(Rj+1)]Di=1f(xi:D:n)[ˉF(xi:D:n)]Ri[ˉF(T)]Rτ, (2.1)

    where Rj is the jth value of the vector R,

    R={(R1,,RD,0,...,0,Rk=nkDj=1Rj),CaseI,(R1,,RD),CaseII,(R1,,Rm),CaseIII, (2.2)

    Rτ is the number of units eliminated at time T, as determined by

    Rτ={0,CaseI,nDDj=1Rj,CaseII,0,CaseIII, (2.3)
    D={kCaseI,DCaseII,mCaseIII, (2.4)

    and

    x_={(x1:m:n,...,xk:m:n),CaseI(x1:m:n,...,xD:m:n),CaseII,(x1:m:n,...,xm:m:n),CaseIII. (2.5)

    The likelihood function of λ,μ under the generalized Type-I PHCS can be derived using (1.1) and (1.2) in (2.1), as

    L(λ,μ;x_)=[Di=1mj=i(Rj+1)]λDμDDi=1xμ1iexp[λW(μ|x_)], (2.6)

    where W(μ|x_)=Di=1(Ri+1)xμi+RτTμ and xi=xi:D:n for simplicity of notation.

    From Equation (2.6), the related log-likelihood function can be found as

    lnL(λ,μ|x_)=const.+D(lnλ+lnμ)+(μ1)Di=1ln(xi)λW(μ|x_), (3.1)

    equating the first derivatives of (3.1) with respect to μ and λ to zero, we obtain

    lnL(λ,μ|x_)λ=DλW(μ|x_)=0, (3.2)
    lnL(λ,μ|x_)μ=Dμ+Di=1ln(xi)λ[Di=1(Ri+1)xμilnxi+RτTμlnT]=0. (3.3)

    The ML estimators of lambdaand mu are then obtained by

    ˆλML(μ)=DW(μ|x_), (3.4)
    ˆμML=DˆλML(μ)[Di=1(Ri+1)xμilnxi+RτTμlnT]. (3.5)

    By using the numerical technique with the Newton-Raphson iteration method, the ML estimates ˆλML and ˆμML can be obtained by solving (3.2) and (3.3), respectively. Due to the invariance property, the related ML estimations of the SF and HF are therefore given by

    ˆSML(t)=exp(ˆλMLtˆμML), (3.6)
    ˆHML(t)=ˆλMLˆμMLtˆμML1. (3.7)

    The observed Fisher information matrix of parameters lambda and mu for large D, is given by

    I(ˆλ,ˆμ)=[2lnL(λ,μ|x_)λ22lnL(λ,μ|x_)λμ2lnL(λ,μ|x_)μλ2lnL(λ,μ|x_)μ2](ˆλML,ˆμML) (3.8)

    where

    2lnL(λ,μ|x_)λ2=Dλ2,
    2lnL(λ,μ|x_)μ2=Dμ2Di=1[λ(Ri+1)+1][(lnxi)2xμi(1+xμi)2],
    2lnL(λ,μ|x_)λμ=[Di=1(Ri+1)xμilnxi(1+xμi)],

    and a 100(1γ)% two-sided approximate confidence intervals for the parameters λ and μ are then

    (ˆλzγ/2V(ˆλ),ˆλ+zγ/2V(ˆλ)), (3.9)

    and

    (ˆμzγ/2V(ˆμ),ˆμ+zγ/2V(ˆμ)), (3.10)

    respectively, where V(ˆλ) and V(ˆμ)are the estimated variances of ˆλML and ˆμML, which are given by the first and the second diagonal element of I1(ˆλ,ˆμ) and zγ/2 is the upper (γ/2) percentile of the standard normal distribution.

    Greene [17] used the delta method to construct the approximate confidence intervals for the SF and HF as a function of the MLEs. This method is used in this subsection to determine the variance of the simpler linear function that can be utilized for inference from large samples, as well as the linear approximation of this function. See Greene [17] and Agresti [18].

    G1=[S(t)λS(t)μ]andG1=[H(t)λH(t)μ] (3.11)

    where

    S(t)λ=tμexp(λtμ),S(t)μ=λtμexp(λtμ)ln(t),

    and

    H(t)λ=μtμ1,H(t)μ=λ[tμ1+μtμ1ln(t)].

    The approximate estimates of V(ˆS(t)) and V(ˆH(t)) are then supplied, respectively, by

    V(ˆS(t))[Gt1I1(λ,μ)G1](ˆλML,ˆμML),V(ˆH(t))[Gt2I1(λ,μ)G2](ˆλML,ˆμML),

    where Gti is the transpose of Gi, i=1,2. These results provide the approximate confidence intervals for S(t) and H(t) are

    (ˆS(t)zγ/2V(ˆS(t)),ˆS(t)+zγ/2V(ˆS(t))) (3.12)

    and

    (ˆH(t)zγ/2V(ˆH(t)),ˆH(t)+zγ/2V(ˆH(t))). (3.13)

    Assuming that both λ and μ are unknown parameters, a natural choice for the prior distributions of λ and μ is to assume that they are independent gamma distributions G(a1,b1) and G(a2,b2), respectively. As a result, the following is the joint prior distribution.

    π(λ,μ)  λa11exp(λb1)μa21exp(b2μ), (4.1)

    a1, b1, a2, b2 are positive constants. If hyperparameters a1, b1, a2, b2 are set as zero, then the informative priors are reduced to the noninformative priors.

    Upon combining (2.6) and (4.1), given the generalized Type-I PHCS, the posterior density function of λ,μ is obtained as

    π(λ,μ|x_)=L(λ,μ|x_)π(λ,μ)/L(λ,μ|x_)π(λ,μ)dλdμ=I1λD+a11μD+a21exp(b2μ)(Di=1xμ1i)exp{λ[W(μ|x_)+b1]}, (4.2)

    where

    I=00λD+a11μD+a21exp(b2μ)(Di=1xμ1i)exp{λ[W(μ|x_)+b1]}dλdμ=Γ(D+a1)0μD+a21(Di=1xμ1i)exp(b2μ)[W(μ|x_)+b1](D+a1)dμ. (4.3)

    Thus, from (1.4), the Bayesian estimates of λ and μ under the SELF are as follows.

    ˆλBS=I1Γ(D+a1+1)0μD+a21(Di=1xμ1i)×exp(b2μ)[W(μ|x_)+b1](D+a1+1)dμ, (4.4)
    ˆμBS=I1Γ(D+a1)0μD+a2(Di=1xμ1i)×exp(b2μ)[W(μ|x_)+b1](D+a1)dμ. (4.5)

    From (1.6), we obtain the Bayesian estimator of λ and μ under the LLF,

    ˆλBL=1υln{I1Γ(D+a1)0μD+a21(Di=1xμ1i)×exp(b2μ)[W(μ|x_)+υ+b1](D+a1)dμ}, (4.6)
    ˆμBL=1υln{I1Γ(D+a1)0μD+a21(Di=1xμ1i)×exp[μ(b2+υ)][W(μ|x_)+b1](D+a1)dμ}. (4.7)

    From (1.8), one obtains the Bayesian estimator of λ and μ under the GELF as follows:

    ˆλBE={I1Γ(D+a1κ)0μD+a21(Di=1xμ1i)×exp(b2μ)[W(μ|x_)+b1](D+a1κ)dμ}1κ, (4.8)
    ˆμBE={I1Γ(D+a1)0μD+a2κ1(Di=1xμ1i)×exp(μb2)[W(μ|x_)+b1](D+a1)dμ}1κ. (4.9)

    Since the integrals in (4.4), (4.5), (4.6), (4.7), (4.8), and (4.9) cannot be computed analytically, the Markov chain Monte Carlo method (MCMC) is used to evaluate these integrals. Depending on the posterior distribution in (4.2), the conditional posterior distributions π1(λ|μ;x_) and π2(μ|λ;x_) of parameters λ and μ can now be computed and written as follows.

    π1(λ|μ;x_)=[W(μ|x_)+b1]Γ(D+a1)λD+a11exp{λ[W(μ|x_)+b1]} (4.10)

    and

    π2(μ|λ;x_)=I1Γ(D+a1)μD+a21exp(b2μ)(Di=1xμ1i)[W(μ|x_)+b1](D+a1). (4.11)

    It is clear that, the posterior density function π1(λ|μ;x_) is a gamma density, therefore, samples of λ can be easily generated. However, the posterior density function π2(μ|λ;x_) is not a specific distribution; therefore, it is not possible to generate samples directly by standard methods. From theorem 2 of Kundu [19], π2(μ|λ;x_) is a log-concave function; therefore, to generate random samples from these distributions, we use the Metropolis-Hastings [20]. The MCMC algorithm can be described as follows.

    Algorithm 1 MCMC method.
    Step 1, start with λ(0)=ˆλML and μ(0)=ˆμML
    Step 2, set i=1
    Step 3, Generate λ(i)GammaDist.[D+a,W(μ(i1)|x_)+b1]=π1(λ|μ(i1);x_)
    Step 4, Generate a proposal μ() from N(μ(i1),V(μ))
    Step 5, Calculate the acceptance probabilities dμ=min[1,π2(μ()|λ(i1))π1(μ(i1)|λ(i1))]
    Step 6, Generate u1 that follows a U(0,1) distribution. If u1dμ, set μ(i)=μ(); otherwise, set μ(i)=μ(i1)
    Step 7, set i=i+1, repeat steps 3 to 7, N times and obtain (λ(j),μ(j)), j=1,2,...,N.
    Step 8, Remove the first B values for λ and μ, which is the burn-in period of λ(j) and μ(j), respectively, where j=1,2,...,NB.

     | Show Table
    DownLoad: CSV

    Assuming g(λ,μ) is an arbitrary function in λ and μ, the Bayesian estimates of g are obtained using the MCMC values as follows.

    Based on SELF, LLF, and GELF, the Bayesian estimates of g are then, respectively, given by

    ^g(λ,μ)BS=1NBNBi=1g(λ(i),μ(i)), (4.12)
    ^g(λ,μ)BL=1υLn[1NBNBi=1eυg(λ(i),μ(i))], (4.13)
    ^g(λ,μ)BE=[1NBNBi=1[g(λ(i),μ(i))]κ]1/κ, (4.14)

    The 100(1γ)% Bayesian confidence interval or credible interval (L,U) for parameter β (β is λ or μ) if

    ULπ(β|x_)dβ=1γ, (4.15)

    Since the integration in (4.15) cannot be solved analytically, the 100(1γ) MCMC-approximated credibility intervals for λ and μ using the (NB) using the (N - B) generated values after sorting in ascending order, (λ(1),λ(2),...,λ(NB)) and (μ(1),μ(2),...,μ(NB)), are given as follows,

    (λ[(NB)γ/2],λ[(NB)(1γ)/2])(μ[(NB)γ/2],μ[(NB)(1γ)/2])

    The absolute difference between the upper and lower bounds determines the length of the credible intervals.

    For ρ=1,2,...,Rj, let Zρ:Rj denote the ρth order statistic out of Rj removed units at stage j. Then, the conditional DF of Zρ:Rj, given the observed generalized Type-I PHCS, is given, as in Basak et al.[21], by

    g(Zρ:Rj|x_)=g(z|x_)=Rj!(ρ1)!(Rjρ)![G(z)G(zj)]ρ1[1G(z)]Rjρg(z)[1G(zj)]Rj,  z>zj, (5.1)

    where

    j={1,...,kifT<Xk:m:n<Xm:m:n,1,...,D,τifXk:m:n<T<Xm:m:n,1,...,mifXk:m:n<Xm:m:n<T,

    with zτ=T.

    By using (1.1) and (1.2) in (5.1), given a generalized Type-I PHCS, the conditional DF of Zρ:Rj is then given as follows:

    g(z|x_)=ρ1q=0Cqλμxμ1exp{λ[ϖq(zμzμj)]},  z>zj, (5.2)

    where Cq=(1)q(ρ1q)Rj!(ρ1)!(Rjρ)! and ϖq=q+Rjρ+1 for q=0,...,ρ1.

    Upon combining (4.2) and (5.2) and using the MCMC technique, the Bayesian predictive DF of Zρ:Rj, given a generalized Type-I PHCS, is obtained as

    g(z|x_)=00g(z|x_)π(λ,μ|x_)dλdμ=1NBNBi=1ρ1q=0Cqλ(i)μ(i)zμ(i)1exp{λ(i)[ϖq(zμ(i)zμ(i)j)]}. (5.3)

    The Bayesian predictive SF of Zρ:Rj, given generalized Type-I PHCS, is given as

    G(t|x_)=tg(z|x_)dx=1NBNBi=1ρ1q=0Cqϖqexp{λ(i)[ϖq(tμ(i)zμ(i)j)]}. (5.4)

    The Bayesian point predictor of Zρ:Rj under the SELF is the mean of the predictive DF, given by

    ˆZρ:Rj=0zg(z|x_)dx,

    Let W1::NW2::NW::N be a future independent progressive Type-II censored sample from the same population with censoring scheme S=(S1,...,S). In this section, we develop a general procedure for deriving the point and interval predictions for Ws::N, 1s, based on the observed generalized Type-I PHCS. The marginal DF of Ws::N is given by Balakrishnan et al. [22] as

    gWs::N(ws|λ)=g(ws|λ)=c(N,s)s1q=0cq,s1[1G(ws)]Mq,s1g(ws), (6.1)

    where 1sρ, c(N,s)=N(NS11)...(NS1...Ss1+1),Mq,s=NS1...Ssq1s+q+1,and cq,s1=(1)q{[qu=1sq+u1υ=sq(Sυ+1)][sq1u=1sq1υ=u(Sυ+1)]}1.

    Upon substituting (1.1) and (1.2) in (6.1), the marginal DF of Ws::N is then obtained as

    g(ws|λ)=c(N,s)s1q=0cq,s1λμyμ1sexp{λ[Mq,swμs]},  ws>0. (6.2)

    Upon combining (4.2)and (6.2) and using the MCMC method, given a generalized Type-I PHCS, the Bayesian predictive DF of Ws::N is obtained as

    g(ws|x_)=00g(ws|x_)π(λ,μ|x_)dλdμ=c(N,s)NBNBi=1s1q=0cq,s1λ(i)μ(i)wμ(i)1sexp{λ(i)[Mq,swμ(i)s]}. (6.3)

    From (6.3), we simply obtain the predictive SF function of Ws::N, given a generalized Type-I PHCS, as

    G(t|x_)=tg(ws|x_)dys=c(N,s)NBNBi=1s1q=0cq,s1Mq,sexp{λ(i)[Mq,stμ(i)]}. (6.4)

    The Bayesian point predictor of Ws::N, 1sm, under the SELF is the mean of the predictive DF, given by

    ˆWs::N=0wsg(ws|x_)dys, (6.5)

    where gWs::N(ws|x_) is given as in (6.3).

    By solving the following two equations, the Bayesian predictive bounds of the 100(1γ)% equi-tailed (ET)interval for Zρ:Rj and Ws::N, 1sm can be obtained respectively,

    G(LET|x_)=γ2andG(UET|x_)=1γ2, (6.6)

    where G(t|x_) is given as in (5.4) and (6.4), where LET and UET denote the lower and upper bounds, respectively. Furthermore, for the highest posterior density (HPD) method, the following two equations need to be solved:

    G(LHPD|x_)G(UHPD|x_)=1γ,

    and

    g(LHPD|x_)g(UHPD|x_)=0,

    where g(z|x_) is as in (5.3) and (6.3), where LHPD and UHPD denote the HPD lower and upper bounds, respectively.

    In this section, a Monte Carlo simulation study was conducted to compare the efficiency of ML and Bayesian estimates. Using different values of n,m,k and T, 5000 generalized Type-I PHCSs were generated from the Weibull distribution (with λ=1 and μ=2). The values of T are chosen such that the three cases of generalized Type-I PHCS occur. Thus, in the first case, a T that lies in the first quarter of the data such that T=Xk:m:n is chosen. In the second case, a T that lies in the third quarter such that T=T is chosen. Finally, a T that is sufficiently large such that T=Xm:m:n is chosen. We computed the ML estimate and the Bayesian estimates of λ, μ, S(t), and H(t) (with t=0.5) under the SELF, LLF (with υ = 0.5) and GELF (with κ = 0.5) using IP and NIP. We also calculated the mean squared error (MSE) and the expected bias (EB) for each estimate.

    The 90% and 95% asymptotic and Bayesian credible confidence intervals with the average length (AL) and the estimated coverage probabilities (CPs) for ˆλ, ˆμ, ^S(t), and ^H(t) are computed.

    Different samples of size (n) with different effective sample sizes (m,k) are used to conduct the simulation study. The process of removing the SF units is performed with these censoring schemes.

    1. Scheme 1: Ri=2(nm)m for odd integers i and Ri=0 for even integers of i.

    2. Scheme 2: Ri=2(nm)m for even integers i and Ri=0 for add integers of i..

    3. Scheme 3: Ri=0 for i=1,2,...,m1, Ri=nm for i=m.

    All these cases have been assumed according to the case of generalized Type-I progressive censoring and all Bayesian results are computed based on two different choices for the hyperparameters (a1,b1,a2,b2).

    1. For the case of IP:a1=200, b1=200, a2=200 and b2=400 (by putting the marginal prior distribution of λ with mean a1b1=1 and small variance a1b21=0.005 and the marginal prior distribution of μ with mean a2b2=1 and variance a2b22=0.005).

    2. For the case of NIP:a1=b1=a2=b2=0.

    The simulated results are displayed in the Appendix of this paper.

    To illustrate all conclusions reached for the Weibull distribution, we used a real data consists of 19 values. These data refer to breakthrough times of an offending liquid between electrodes at a voltage of 34 kilovolts, as prepared by Viveros and Balakrishnan in [23] from Table 6.1 of Nelson ([24], p.228). We will use these real data to consider the following progressively censored schemes.

    Suppose m=10, R=(0,0,3,0,0,3,0,0,3,0), Then, we have the following progressive data: 0.19, 0.78, 0.96, 2.78, 3.16, 4.15, 4.85, 7.35, 8.01, and 31.75. If we consider a different T, then we have three different generalized Type-I PHCSs.

    1. Scheme I: Suppose T=4. Since T<X7:10:19<X10:10:19, then the experiment would have terminated at X7:7:19, with R=(0,0,3,0,0,0,9) and Rτ=0 and we would have the following data: 0.19, 0.78, 0.96, 2.78, 3.16, 4.15, and 4.67.

    2. Scheme II: Suppose T=7.5. Since X7:10:19<T<X10:10:19, then the experiment would have terminated at T=8, with R = (0, 0, 3, 0, 0, 3, 0, 0) and Rτ=5 and we would have the following data: 0.19, 0.78, 0.96, 2.78, 3.16, 4.15, 4.85, and 7.35.

    3. Scheme III: Suppose k=7 and T=35. Since X7:10:19<X10:10:19<T, then the experiment would have terminated at X10:10:19, with R=R and Rτ=0 and we would have the following data: 0.19, 0.78, 0.96, 2.78, 3.16, 4.15, 4.85, 7.35, 8.01, and 31.75.

    Based on the generated generalized Type-I PHCS and two different choices of hyperparameters (a1,b1,a2,b2) as in the Monte Carlo simulation, Table 1 shows the point predictor and 95% Bayesian prediction bounds of Zρ:Rk for three different censoring schemes, and Table 2 shows the point predictor and 95% Bayesian prediction bounds of Ws::N from the future progressively censored sample of size =10 from a sample of size N=20 with progressive censoring scheme S=(0,0,3,0,0,3,0,0,3,1) for the previous four censoring schemes.

    Table 1.  Bayesian point predictor and 95% ET and HPD prediction intervals for Zρ:Rj for ρ=1,...,Rj, and j=1,...,D,τ.
    IP NIP
    Sch. j ρ ˆXρ:Rj ET interval HPD interval ˆXρ:Rj ET interval HPD interval
    1 3 1 4.824 (1.322, 21.783) (1.214, 17.062) 6.410 (1.324, 23.275) (1.214, 18.034)
    2 10.634 (2.417, 42.868) (1.319, 34.499) 14.202 (2.429, 46.302) (1.308, 36.810)
    3 22.254 (5.271, 86.933) (2.348, 70.530) 29.787 (5.289, 94.280) (2.274, 75.524)
    7 1 5.914 (5.943, 12.764) (5.908, 11.190) 7.639 (5.944, 13.261) (5.908, 11.514)
    2 7.367 (6.254, 17.586) (5.939, 15.267) 9.587 (6.258, 18.558) (5.935, 15.923)
    3 9.027 (6.817, 22.790) (6.182, 19.570) 11.814 (6.821, 24.302) (6.071, 20.612)
    4 10.964 (7.581, 28.762) (6.654, 24.889) 14.411 (7.581, 30.909) (6.608, 26.363)
    5 13.288 (8.553, 35.920) (7.294, 31.039) 17.528 (8.544, 38.832) (7.213, 33.049)
    6 16.192 (9.782, 44.951) (8.125, 38.766) 21.424 (9.761, 48.820) (8.000, 41.448)
    7 20.066 (11.390, 57.239) (9.351, 48.369) 26.619 (11.351, 62.390) (9.026, 52.794)
    8 25.877 (13.657, 76.426) (10.679, 65.357) 34.412 (13.592, 83.499) (10.421, 70.278)
    9 37.497 (17.494,118.537) (12.895, 99.972) 49.997 (17.400,129.445) (12.532,107.555)
    2 3 1 4.924 (1.330, 21.776) (1.214, 17.251) 6.488 (1.332, 22.842) (1.214, 17.983)
    2 10.886 (2.506, 42.386) (1.343, 34.584) 14.399 (2.526, 44.762) (1.337, 36.266)
    3 22.809 (5.601, 85.629) (5.198, 69.693) 30.221 (5.656, 90.660) (5.227, 73.313)
    6 1 8.082 (5.365, 25.811) (5.250, 21.286) 10.524 (5.367, 26.877) (5.250, 22.019)
    2 14.044 (6.541, 46.422) (5.379, 38.619) 18.435 (6.562, 48.797) (5.372, 40.302)
    3 25.967 (9.637, 89.664) (9.233, 73.728) 34.256 (9.691, 94.695) (9.262, 77.348)
    9 1 10.305 (10.188, 22.456) (10.120, 19.742) 13.284 (10.191, 23.096) (10.120, 20.181)
    2 13.285 (10.826, 32.161) (10.192, 28.030) 17.239 (10.837, 33.440) (10.190, 28.937)
    3 17.260 (12.126, 44.641) (12.105, 38.397) 22.513 (12.152, 46.768) (10.856, 39.936)
    4 23.220 (14.248, 63.813) (12.029, 55.213) 30.425 (14.288, 67.225) (11.978, 57.679)
    5 35.144 (18.060,105.916) (14.149, 90.288) 46.246 (18.126,111.946) (14.055, 94.654)
    3 3 1 5.061 (1.335, 22.283) (1.214, 17.716) 6.661 (1.337, 23.291) (1.214, 18.425)
    2 11.226 (2.572, 43.235) (1.356, 35.439) 14.832 (2.597, 45.441) (1.351, 37.039)
    3 23.556 (5.834, 87.257) (2.664, 72.209) 31.172 (5.910, 91.905) (2.639, 75.613)
    6 1 8.219 (5.370, 26.318) (5.250, 21.752) 10.697 (5.372, 27.327) (5.250, 22.460)
    2 14.384 (6.607, 47.271) (5.391, 39.474) 18.867 (6.632, 49.477) (5.386, 41.075)
    3 26.714 (9.870, 91.293) (6.612, 75.361) 35.207 (9.945, 95.940) (6.674, 79.648)
    9 1 26.714 (9.870, 91.293) (9.142, 75.361) 15.580 (10.255, 32.209) (10.133, 27.343)
    2 18.205 (11.490, 52.153) (10.274, 44.357) 23.750 (11.515, 54.360) (10.269, 45.957)
    3 30.536 (14.752, 96.175) (11.495, 80.244) 40.090 (14.828,100.823) (11.514, 83.663)

     | Show Table
    DownLoad: CSV
    Table 2.  Bayesian point predictor and 95% ET and HPD prediction intervals Ws::N for s=1,...,.
    IP NIP
    Sch. s ˆYs:N ET interval HPD interval ˆYs:N ET interval HPD interval
    1 1 0.704 (0.016, 2.927) (0.000, 2.255) 0.739 (0.016, 3.139) (0.000, 2.393)
    2 0.972 (0.143, 4.811) (0.013, 3.858) 1.014 (0.144, 5.212) (0.012, 4.127)
    3 1.314 (0.361, 6.671) (0.114, 5.470) 1.381 (0.362, 7.270) (0.106, 5.878)
    4 1.760 (0.668, 9.119) (0.299, 7.574) 1.861 (0.668, 9.976) (0.281, 8.162)
    5 2.216 (1.036, 11.675) (0.545, 9.782) 2.356 (1.032, 12.810) (0.514, 10.566)
    6 2.696 (1.457, 14.399) (0.842, 12.142) 2.878 (1.448, 15.838) (0.794, 13.139)
    7 3.481 (2.039, 18.751) (1.237, 15.844) 3.724 (2.023, 20.644) (1.169, 17.159)
    8 4.352 (2.726, 23.618) (1.717, 20.008) 4.666 (2.702, 26.033) (1.622, 21.689)
    9 5.356 (3.544, 29.252) (2.293, 24.833) 5.753 (3.509, 32.275) (2.167, 26.942)
    10 9.350 (5.264, 50.149) (3.233, 41.790) 9.952 (5.218, 54.977) (3.068, 45.151)
    2 1 0.722 (0.017, 2.926) (0.000, 2.282) 0.750 (0.017, 3.077) (0.000, 2.386)
    2 0.978 (0.154, 4.751) (0.016, 3.865) 1.060 (0.156, 5.028) (0.016, 4.061)
    3 1.308 (0.391, 6.536) (0.134, 5.450) 1.423 (0.396, 6.943) (0.131, 5.742)
    4 1.738 (0.727, 8.892) (0.350, 7.520) 1.898 (0.734, 9.468) (0.341, 7.938)
    5 2.172 (1.132, 11.338) (0.638, 9.684) 2.382 (1.140, 12.097) (0.622, 10.237)
    6 2.627 (1.596, 13.939) (0.984, 11.990) 2.890 (1.606, 14.898) (0.959, 12.690)
    7 3.380 (2.238, 18.128) (1.444, 15.628) 3.726 (2.249, 19.387) (1.408, 16.549)
    8 4.213 (3.000, 22.800) (2.003, 19.709) 4.650 (3.011, 24.402) (1.954, 20.885)
    9 5.168 (3.905, 28.199) (2.675, 24.436) 5.714 (3.916, 30.202) (2.608, 25.909)
    10 9.146 (5.795, 48.785) (3.750, 41.359) 10.042 (5.814, 52.007) (3.667, 43.723)
    3 1 0.748 (0.017, 2.998) (0.000, 2.348) 0.775 (0.018, 3.142) (0.000, 2.449)
    2 1.042 (0.162, 4.847) (0.018, 3.964) 1.051 (0.164, 5.104) (0.017, 4.150)
    3 1.386 (0.412, 6.650) (0.146, 5.579) 1.405 (0.419, 7.024) (0.144, 5.854)
    4 1.836 (0.768, 9.030) (0.380, 7.686) 1.867 (0.779, 9.557) (0.374, 8.077)
    5 2.288 (1.196, 11.496) (0.691, 9.887) 2.335 (1.211, 12.187) (0.680, 10.403)
    6 2.761 (1.690, 14.117) (1.066, 12.229) 2.825 (1.708, 14.987) (1.050, 12.881)
    7 3.551 (2.371, 18.349) (1.564, 15.931) 3.637 (2.394, 19.492) (1.541, 16.788)
    8 4.418 (3.181, 23.064) (2.170, 20.083) 4.534 (3.209, 24.515) (2.137, 21.175)
    9 5.414 (4.142, 28.510) (2.897, 24.888) 5.563 (4.176, 30.322) (2.855, 26.255)
    10 9.635 (6.145, 49.504) (4.051, 42.221) 9.839 (6.198, 52.438) (4.002, 44.426)

     | Show Table
    DownLoad: CSV

    The Bayesian and ML estimates of the unknown parameters and the SF and HF of the Weibull distribution when the observed sample is a generalized Type-I PHCS sample are obtained. In the Bayesian approach, the SELF, LLF and GELF based on IP and NIP distributions are considered. The 90% and 95% asymptotic and credible confidence intervals for the parameters and for the SF and HF are also constructed. The Bayesian point and interval predictions of future order statistics samples from the same population for a progressive Type-II of an unpredictable future sample were also developed. From the numerical results, we derive the following conclusions:

    1. From Tables 12, the HPD prediction intervals appear to be more accurate than the ET prediction intervals, and the means of the Bayesian point predictor inside the Bayesian prediction intervals.

    2. From Tables 36 in the appendix, the Bayesian estimates using the IP are better than the MLEs. Furthermore, the results of the ML estimates are similar to the Bayesian estimators with NIP. Thus, when we have no prior knowledge of the unknown parameters, it is often easier to use the ML instead of the Bayesian estimators, since the computation of the Bayesian estimator is more complicated. Moreover, in most cases, the MSE decreases as n and m increase.

    Table 3.  MSE and EB of ML and Bayesian estimates for λ based on the different censoring schemes.
    Bayesian
    {ˆλBS {ˆλBL {ˆλBE
    Sch. T (n,m,k) ˆλML IP NIP IP NIP IP NIP
    MSE
    SchI T=0.3 (30, 20, 15) 0.5082 0.0244 0.5305 0.0239 0.3282 0.0243 0.3739
    (40, 20, 15) 0.5186 0.0192 0.5693 0.0187 0.3517 0.0190 0.4026
    (60, 30, 20) 0.4127 0.0173 0.4355 0.0170 0.2675 0.0171 0.3403
    T=0.7 (30, 20, 15) 0.2879 0.0259 0.2666 0.0252 0.2114 0.0255 0.2243
    (40, 20, 15) 0.6400 0.0203 0.6240 0.0199 0.3760 0.0202 0.4454
    (60, 30, 20) 0.2110 0.0172 0.2007 0.0170 0.1646 0.0172 0.1708
    T=1.5 (30, 20, 15) 0.2843 0.0250 0.2671 0.0242 0.2085 0.0245 0.2198
    (40, 20, 15) 0.5891 0.0226 0.5973 0.0222 0.3726 0.0225 0.4423
    (60, 30, 20) 0.2528 0.0175 0.2440 0.0171 0.1921 0.0172 0.2036
    SchII T=0.3 (30, 20, 15) 0.5166 0.0252 0.5284 0.0245 0.3486 0.0250 0.3869
    (40, 20, 15) 0.5489 0.0197 0.5772 0.0194 0.3644 0.0197 0.4159
    (60, 30, 20) 0.3080 0.0174 0.3002 0.0172 0.2285 0.0174 0.2459
    T=0.7 (30, 20, 15) 0.3489 0.0255 0.3314 0.0247 0.2473 0.0250 0.2673
    (40, 20, 15) 0.5221 0.0191 0.5308 0.0187 0.3333 0.0190 0.3778
    (60, 30, 20) 0.2269 0.0164 0.2135 0.0160 0.1734 0.0162 0.1794
    T=1.5 (30, 20, 15) 0.3369 0.0265 0.3188 0.0256 0.2451 0.0259 0.2584
    (40, 20, 15) 0.6190 0.0205 0.6676 0.0198 0.3925 0.0200 0.4631
    (60, 30, 20) 0.2130 0.0177 0.2087 0.0173 0.1658 0.0174 0.1737
    SchIII T=0.3 (30, 20, 15) 0.5166 0.0252 0.5284 0.0245 0.3486 0.0250 0.3869
    (40, 20, 15) 1.4205 0.0173 2.3081 0.0169 0.7138 0.0171 1.1274
    (60, 30, 20) 0.3416 0.0162 0.3652 0.0159 0.2586 0.0161 0.2772
    T=0.7 (30, 20, 15) 0.5049 0.0246 0.5692 0.0238 0.3290 0.0241 0.4095
    (40, 20, 15) 1.2471 0.0183 1.7174 0.0179 0.6258 0.0181 0.9441
    (60, 30, 20) 0.3569 0.0152 0.3705 0.0149 0.2577 0.0151 0.2792
    T=1.5 (30, 20, 15) 0.4781 0.0246 0.5283 0.0238 0.3279 0.0241 0.3805
    (40, 20, 15) 1.4825 0.0182 2.0789 0.0179 0.6943 0.0181 1.0823
    (60, 30, 20) 0.3832 0.0164 0.4044 0.0161 0.2737 0.0163 0.3012
    EB
    SchI T=0.3 (30, 20, 15) 0.1962 0.0036 0.1983 0.0069 0.1024 0.0121 0.0855
    (40, 20, 15) 0.1816 0.0052 0.1950 0.0036 0.0900 0.0079 0.0715
    (60, 30, 20) 0.1219 0.0057 0.1268 0.0019 0.0649 0.0057 0.0502
    T=0.7 (30, 20, 15) 0.1114 0.0075 0.0936 0.0029 0.0436 0.0080 0.0274
    (40, 20, 15) 0.2209 0.0041 0.2048 0.0046 0.1182 0.0089 0.1086
    (60, 30, 20) 0.0984 0.0019 0.0884 0.0054 0.0519 0.0090 0.0403
    T=1.5 (30, 20, 15) 0.1340 0.0092 0.1151 0.0012 0.0662 0.0063 0.0516
    (40, 20, 15) 0.1950 0.0010 0.1840 0.0077 0.1037 0.0119 0.0935
    (60, 30, 20) 0.1235 0.0052 0.1125 0.0021 0.0748 0.0058 0.0647
    SchII T=0.3 (30, 20, 15) 0.2021 0.0034 0.2015 0.0070 0.1070 0.0122 0.0894
    (40, 20, 15) 0.1772 0.0006 0.1840 0.0079 0.0827 0.0122 0.0649
    (60, 30, 20) 0.1107 0.0002 0.1118 0.0072 0.0542 0.0109 0.0379
    T=0.7 (30, 20, 15) 0.1516 0.0109 0.1333 0.0007 0.0785 0.0044 0.0645
    (40, 20, 15) 0.2083 0.0036 0.2028 0.0049 0.1182 0.0091 0.1067
    (60, 30, 20) 0.1205 0.0051 0.1060 0.0021 0.0684 0.0057 0.0573
    T=1.5 (30, 20, 15) 0.1597 0.0103 0.1411 0.0001 0.0889 0.0051 0.0757
    (40, 20, 15) 0.2560 0.0116 0.2477 0.0030 0.1533 0.0012 0.1453
    (60, 30, 20) 0.1101 0.0089 0.1001 0.0016 0.0636 0.0020 0.0529
    SchIII T=0.3 (30, 20, 15) 0.1928 0.0034 0.2015 0.0070 0.1070 0.0122 0.0894
    (40, 20, 15) 0.3861 0.0032 0.4732 0.0048 0.2402 0.0088 0.2642
    (60, 30, 20) 0.1597 0.0022 0.1710 0.0046 0.1106 0.0081 0.1002
    T=0.7 (30, 20, 15) 0.1877 0.0107 0.1846 0.0008 0.1130 0.0040 0.1052
    (40, 20, 15) 0.3373 0.0014 0.4115 0.0066 0.2144 0.0106 0.2268
    (60, 30, 20) 0.1610 0.0039 0.1703 0.0030 0.1106 0.0064 0.1009
    T=1.5 (30, 20, 15) 0.1982 0.0107 0.1950 0.0007 0.1223 0.0041 0.1140
    (40, 20, 15) 0.3659 0.0018 0.4368 0.0062 0.2275 0.0103 0.2443
    (60, 30, 20) 0.1717 0.0001 0.1788 0.0068 0.1167 0.0103 0.1076

     | Show Table
    DownLoad: CSV
    Table 4.  MSE and EB of the ML and Bayesian estimates for µ based on the different censoring schemes.
    Bayesian
    ˆμBS ˆμBL ˆμBE
    Sch. T (n,m,k) ˆμML IP NIP IP NIP IP NIP
    MSE
    SchI T=0.3 (30, 20, 15) 0.0410 0.0066 0.0361 0.0065 0.0337 0.0064 0.0320
    (40, 20, 15) 0.0307 0.0051 0.0270 0.0051 0.0257 0.0050 0.0250
    (60, 30, 20) 0.0236 0.0046 0.0214 0.0046 0.0207 0.0046 0.0203
    T=0.7 (30, 20, 15) 0.0287 0.0070 0.0246 0.0068 0.0235 0.0066 0.0229
    (40, 20, 15) 0.0304 0.0054 0.0259 0.0053 0.0248 0.0051 0.0239
    (60, 30, 20) 0.0187 0.0047 0.0163 0.0046 0.0158 0.0046 0.0155
    T=1.5 (30, 20, 15) 0.0301 0.0069 0.0257 0.0067 0.0246 0.0066 0.0238
    (40, 20, 15) 0.0299 0.0060 0.0259 0.0059 0.0248 0.0058 0.0240
    (60, 30, 20) 0.0185 0.0047 0.0161 0.0046 0.0156 0.0046 0.0152
    SchII T=0.3 (30, 20, 15) 0.0459 0.0069 0.0409 0.0067 0.0382 0.0066 0.0364
    (40, 20, 15) 0.0310 0.0054 0.0272 0.0054 0.0259 0.0053 0.0253
    (60, 30, 20) 0.0215 0.0046 0.0190 0.0045 0.0184 0.0044 0.0180
    T=0.7 (30, 20, 15) 0.0287 0.0066 0.0248 0.0066 0.0237 0.0064 0.0228
    (40, 20, 15) 0.0256 0.0052 0.0220 0.0051 0.0210 0.0050 0.0202
    (60, 30, 20) 0.0176 0.0042 0.0153 0.0041 0.0148 0.0041 0.0144
    T=1.5 (30, 20, 15) 0.0308 0.0069 0.0268 0.0067 0.0255 0.0066 0.0246
    (40, 20, 15) 0.0279 0.0053 0.0243 0.0053 0.0231 0.0052 0.0221
    (60, 30, 20) 0.0161 0.0046 0.0140 0.0045 0.0136 0.0044 0.0133
    SchIII T=0.3 (30, 20, 15) 0.0459 0.0069 0.0409 0.0067 0.0382 0.0066 0.0364
    (40, 20, 15) 0.0462 0.0046 0.0423 0.0046 0.0393 0.0046 0.0370
    (60, 30, 20) 0.0248 0.0043 0.0226 0.0042 0.0216 0.0042 0.0207
    T=0.7 (30, 20, 15) 0.0350 0.0062 0.0304 0.0062 0.0286 0.0061 0.0272
    (40, 20, 15) 0.0428 0.0051 0.0394 0.0050 0.0369 0.0049 0.0348
    (60, 30, 20) 0.0232 0.0041 0.0208 0.0040 0.0199 0.0040 0.0192
    T=1.5 (30, 20, 15) 0.0401 0.0067 0.0354 0.0066 0.0333 0.0065 0.0318
    (40, 20, 15) 0.0469 0.0050 0.0420 0.0050 0.0392 0.0049 0.0371
    (60, 30, 20) 0.0254 0.0045 0.0224 0.0044 0.0214 0.0043 0.0205
    EB
    SchI T=0.3 (30, 20, 15) 0.0556 0.0107 0.0453 0.0083 0.0378 0.0038 0.0247
    (40, 20, 15) 0.0338 0.0057 0.0263 0.0039 0.0204 0.0006 0.0095
    (60, 30, 20) 0.0248 0.0047 0.0194 0.0032 0.0150 0.0003 0.0069
    T=0.7 (30, 20, 15) 0.0335 0.0084 0.0246 0.0061 0.0194 0.0015 0.0096
    (40, 20, 15) 0.0446 0.0077 0.0333 0.0059 0.0285 0.0025 0.0198
    (60, 30, 20) 0.0269 0.0064 0.0210 0.0050 0.0178 0.0021 0.0118
    T=1.5 (30, 20, 15) 0.0426 0.0090 0.0324 0.0067 0.0273 0.0022 0.0181
    (40, 20, 15) 0.0439 0.0092 0.0337 0.0074 0.0291 0.0041 0.0205
    (60, 30, 20) 0.0319 0.0063 0.0260 0.0048 0.0229 0.0020 0.0171
    SchII T=0.3 (30, 20, 15) 0.0592 0.0104 0.0480 0.0081 0.0403 0.0036 0.0272
    (40, 20, 15) 0.0350 0.0081 0.0258 0.0064 0.0200 0.0030 0.0093
    (60, 30, 20) 0.0262 0.0073 0.0200 0.0058 0.0157 0.0030 0.0077
    T=0.7 (30, 20, 15) 0.0438 0.0082 0.0348 0.0059 0.0293 0.0015 0.0194
    (40, 20, 15) 0.0426 0.0073 0.0339 0.0056 0.0291 0.0023 0.0203
    (60, 30, 20) 0.0305 0.0056 0.0224 0.0042 0.0192 0.0014 0.0133
    T=1.5 (30, 20, 15) 0.0473 0.0086 0.0378 0.0062 0.0327 0.0018 0.0234
    (40, 20, 15) 0.0494 0.0045 0.0384 0.0028 0.0335 0.0005 0.0248
    (60, 30, 20) 0.0239 0.0031 0.0184 0.0017 0.0153 0.0011 0.0095
    SchIII T=0.3 (30, 20, 15) 0.0592 0.0104 0.0480 0.0081 0.0403 0.0036 0.0272
    (40, 20, 15) 0.0701 0.0073 0.0608 0.0057 0.0534 0.0026 0.0413
    (60, 30, 20) 0.0404 0.0066 0.0353 0.0051 0.0310 0.0024 0.0233
    T=0.7 (30, 20, 15) 0.0516 0.0070 0.0422 0.0048 0.0360 0.0005 0.0252
    (40, 20, 15) 0.0656 0.0084 0.0581 0.0068 0.0510 0.0037 0.0391
    (60, 30, 20) 0.0388 0.0054 0.0332 0.0040 0.0291 0.0013 0.0215
    T=1.5 (30, 20, 15) 0.0561 0.0073 0.0464 0.0050 0.0402 0.0007 0.0296
    (40, 20, 15) 0.0685 0.0077 0.0595 0.0061 0.0524 0.0030 0.0404
    (60, 30, 20) 0.0444 0.0082 0.0375 0.0068 0.0332 0.0041 0.0256

     | Show Table
    DownLoad: CSV
    Table 5.  MSE and EB of the ML and Bayesian estimates for S(t) at the different censoring schemes.
    Bayesian
    ^S(t)BS ^S(t)BL ^S(t)BE
    Sch. T (n,m,k) ^S(t)ML IP NIP IP NIP IP NIP
    MSE
    SchI T=0.3 (30, 20, 15) 0.0005 3.90×106 0.0016 3.90×106 0.0014 2.60×106 0.0003
    (40, 20, 15) 0.0010 3.90×106 0.0026 3.90×106 0.0025 1.30×106 0.0004
    (60, 30, 20) 0.0007 3.90×106 0.0016 3.90×106 0.0014 2.60×106 0.0004
    T=0.7 (30, 20, 15) 0.0005 5.20×106 0.0012 5.20×106 0.0010 2.60×106 0.0003
    (40, 20, 15) 0.0007 3.90×106 0.0014 3.90×106 0.0014 2.60×106 0.0004
    (60, 30, 20) 0.0003 5.20×106 0.0007 5.20×106 0.0007 2.60×106 0.0003
    T=1.5 (30, 20, 15) 0.0003 3.90×106 0.0008 3.90×106 0.0008 2.60×106 0.0003
    (40, 20, 15) 0.0005 5.20×106 0.0012 5.20×106 0.0012 2.60×106 0.0004
    (60, 30, 20) 0.0003 5.20×106 0.0005 5.20×106 0.0005 2.60×106 0.0001
    SchII T=0.3 (30, 20, 15) 0.0007 3.90×106 0.0018 3.90×106 0.0017 2.60×106 0.0004
    (40, 20, 15) 0.0012 3.90×106 0.0029 3.90×106 0.0027 2.60×106 0.0005
    (60, 30, 20) 0.0008 3.90×106 0.0017 3.90×106 0.0016 2.60×106 0.0005
    T=0.7 (30, 20, 15) 0.0005 5.20×106 0.0010 5.20×106 0.0010 2.60×106 0.0004
    (40, 20, 15) 0.0005 3.90×106 0.0012 3.90×106 0.0012 2.60×106 0.0003
    (60, 30, 20) 0.0003 5.20×106 0.0005 5.20×106 0.0005 2.60×106 0.0001
    T=1.5 (30, 20, 15) 0.0004 5.20×106 0.0008 5.20×106 0.0008 2.60×106 0.0003
    (40, 20, 15) 0.0004 3.90×106 0.0009 3.90×106 0.0009 2.60×106 0.0003
    (60, 30, 20) 0.0003 5.20×106 0.0004 5.20×106 0.0004 2.60×106 0.0001
    SchIII T=0.3 (30, 20, 15) 0.0007 3.90×106 0.0018 3.90×106 0.0017 2.60×106 0.0004
    (40, 20, 15) 0.0007 2.60×106 0.0017 2.60×106 0.0016 1.30×106 0.0004
    (60, 30, 20) 0.0004 3.90×106 0.0008 3.90×106 0.0008 2.60×106 0.0003
    T=0.7 (30, 20, 15) 0.0003 3.90×106 0.0007 3.90×106 0.0007 2.60×106 0.0003
    (40, 20, 15) 0.0007 3.90×106 0.0017 3.90×106 0.0016 1.30×106 0.0004
    (60, 30, 20) 0.0003 3.90×106 0.0007 3.90×106 0.0007 2.60×106 0.0001
    T=1.5 (30, 20, 15) 0.0003 3.90×106 0.0007 3.90×106 0.0007 2.60×106 0.0001
    (40, 20, 15) 0.0008 3.90×106 0.0018 3.90×106 0.0017 1.30×106 0.0004
    (60, 30, 20) 0.0003 3.90×106 0.0007 3.90×106 0.0007 2.60×106 0.0001
    EB
    SchI T=0.3 (30, 20, 15) 0.0070 0.0014 0.0270 0.0014 0.0260 0.0007 0.0014
    (40, 20, 15) 0.0120 0.0014 0.0350 0.0014 0.0340 0.0007 0.0003
    (60, 30, 20) 0.0090 0.0013 0.0250 0.0013 0.0250 0.0007 0.0004
    T=0.7 (30, 20, 15) 0.0069 0.0014 0.0220 0.0013 0.0210 0.0007 0.0009
    (40, 20, 15) 0.0073 0.0013 0.0230 0.0013 0.0230 0.0007 0.0007
    (60, 30, 20) 0.0049 0.0014 0.0150 0.0013 0.0150 0.0005 0.0003
    T=1.5 (30, 20, 15) 0.0045 0.0012 0.0170 0.0012 0.0170 0.0008 0.0004
    (40, 20, 15) 0.0069 0.0014 0.0220 0.0014 0.0220 0.0007 0.0001
    (60, 30, 20) 0.0032 0.0012 0.0120 0.0012 0.0120 0.0007 0.0008
    SchII T=0.3 (30, 20, 15) 0.0082 0.0014 0.0280 0.0014 0.0280 0.0007 0.0003
    (40, 20, 15) 0.0130 0.0014 0.0360 0.0014 0.0350 0.0007 0.0010
    (60, 30, 20) 0.0096 0.0014 0.0250 0.0014 0.0250 0.0007 0.0010
    T=0.7 (30, 20, 15) 0.0055 0.0012 0.0190 0.0012 0.0190 0.0008 0.0010
    (40, 20, 15) 0.0062 0.0013 0.0210 0.0013 0.0210 0.0007 0.0008
    (60, 30, 20) 0.0039 0.0013 0.0140 0.0013 0.0140 0.0007 0.0003
    T=1.5 (30, 20, 15) 0.0045 0.0013 0.0170 0.0012 0.0160 0.0008 0.0003
    (40, 20, 15) 0.0038 0.0012 0.0190 0.0012 0.0180 0.0008 0.0021
    (60, 30, 20) 0.0034 0.0013 0.0130 0.0013 0.0120 0.0007 0.0008
    SchIII T=0.3 (30, 20, 15) 0.0082 0.0014 0.0280 0.0014 0.0280 0.0007 0.0003
    (40, 20, 15) 0.0074 0.0013 0.0260 0.0013 0.0260 0.0008 0.0025
    (60, 30, 20) 0.0055 0.0013 0.0170 0.0013 0.0170 0.0007 0.0010
    T=0.7 (30, 20, 15) 0.0035 0.0013 0.0170 0.0012 0.0160 0.0008 0.0020
    (40, 20, 15) 0.0070 0.0013 0.0260 0.0013 0.0260 0.0008 0.0027
    (60, 30, 20) 0.0041 0.0013 0.0150 0.0013 0.0150 0.0007 0.0018
    T=1.5 (30, 20, 15) 0.0039 0.0012 0.0170 0.0012 0.0160 0.0008 0.0017
    (40, 20, 15) 0.0080 0.0014 0.0270 0.0013 0.0260 0.0007 0.0020
    (60, 30, 20) 0.0042 0.0013 0.0150 0.0013 0.0150 0.0007 0.0018

     | Show Table
    DownLoad: CSV
    Table 6.  MSE and EB of the ML and Bayesian estimates for H(t) at different censoring schemes.
    Bayesian
    ^H(t)BS ^H(t)BL ^H(t)BE
    Sch. T (n,m,k) ^H(t)ML IP NIP IP NIP IP NIP
    MSE
    SchI T=0.3 (30, 20, 15) 0.0250 4.20×105 0.0390 4.20×105 0.0320 4.20×105 0.0200
    (40, 20, 15) 0.0220 4.20×105 0.0350 4.20×105 0.0300 4.20×105 0.0190
    (60, 30, 20) 0.0250 5.60×105 0.0370 5.60×105 0.0270 5.60×105 0.0240
    T=0.7 (30, 20, 15) 0.0110 5.60×105 0.0130 5.60×105 0.0130 7.00×105 0.0095
    (40, 20, 15) 0.0290 5.60×105 0.0400 5.60×105 0.0330 5.60×105 0.0220
    (60, 30, 20) 0.0084 8.40×105 0.0110 8.40×105 0.0100 8.40×105 0.0081
    T=1.5 (30, 20, 15) 0.0120 7.00×105 0.0150 7.00×105 0.0140 7.00×105 0.0110
    (40, 20, 15) 0.0240 5.60×105 0.0350 5.60×105 0.0300 5.60×105 0.0210
    (60, 30, 20) 0.0100 7.00×105 0.0130 8.40×105 0.0120 8.40×105 0.0095
    SchII T=0.3 (30, 20, 15) 0.0260 4.20×105 0.0390 4.20×105 0.0340 5.60×105 0.0220
    (40, 20, 15) 0.0220 4.20×105 0.0340 4.20×105 0.0300 4.20×105 0.0190
    (60, 30, 20) 0.0120 5.60×105 0.0170 5.60×105 0.0150 5.60×105 0.0110
    T=0.7 (30, 20, 15) 0.0130 5.60×105 0.0180 5.60×105 0.0170 7.00×105 0.0120
    (40, 20, 15) 0.0190 5.60×105 0.0280 5.60×105 0.0250 5.60×105 0.0160
    (60, 30, 20) 0.0086 7.00×105 0.0110 7.00×105 0.0110 8.40×105 0.0081
    T=1.5 (30, 20, 15) 0.0130 7.00×105 0.0170 7.00×105 0.0160 7.00×105 0.0120
    (40, 20, 15) 0.0260 4.20×105 0.0420 4.20×105 0.0350 5.60×105 0.0230
    (60, 30, 20) 0.0076 7.00×105 0.0100 7.00×105 0.0096 7.00×105 0.0074
    SchIII T=0.3 (30, 20, 15) 0.0260 4.20×105 0.0390 4.20×105 0.0340 5.60×105 0.0220
    (40, 20, 15) 0.0750 4.20×105 0.2200 4.20×105 0.1100 4.20×105 0.0680
    (60, 30, 20) 0.0150 5.60×105 0.0230 5.60×105 0.0210 5.60×105 0.0140
    T=0.7 (30, 20, 15) 0.0260 5.60×105 0.0430 5.60×105 0.0340 5.60×105 0.0240
    (40, 20, 15) 0.0660 4.20×105 0.1500 4.20×105 0.0910 4.20×105 0.0570
    (60, 30, 20) 0.0160 5.60×105 0.0230 5.60×105 0.0210 5.60×105 0.0140
    T=1.5 (30, 20, 15) 0.0250 5.60×105 0.0430 5.60×105 0.0340 5.60×105 0.0230
    (40, 20, 15) 0.0870 4.20×105 0.2000 4.20×105 0.1000 4.20×105 0.0700
    (60, 30, 20) 0.0170 5.60×105 0.0260 5.60×105 0.0230 5.60×105 0.0150
    EB
    SchI T=0.3 (30, 20, 15) 0.0600 1.70×104 0.0880 3.20×104 0.0800 0.0027 0.0320
    (40, 20, 15) 0.0510 3.60×104 0.0810 5.20×104 0.0730 0.0028 0.0240
    (60, 30, 20) 0.0360 2.80×105 0.0540 1.10×104 0.0490 0.0024 0.0180
    T=0.7 (30, 20, 15) 0.0330 3.80×104 0.0400 5.20×104 0.0370 0.0028 0.0110
    (40, 20, 15) 0.0610 9.80×105 0.0810 5.60×105 0.0740 0.0024 0.0370
    (60, 30, 20) 0.0290 1.10×105 0.0370 1.50×104 0.0350 0.0024 0.0160
    T=1.5 (30, 20, 15) 0.0400 2.40×104 0.0480 9.80×105 0.0450 0.0021 0.0200
    (40, 20, 15) 0.0550 1.50×104 0.0740 3.10×104 0.0680 0.0025 0.0330
    (60, 30, 20) 0.0340 5.90×104 0.0440 4.50×104 0.0420 0.0017 0.0230
    SchII T=0.3 (30, 20, 15) 0.0640 3.40×104 0.0920 4.90×104 0.0840 0.0028 0.0350
    (40, 20, 15) 0.0510 3.50×104 0.0780 5.00×104 0.0700 0.0028 0.0230
    (60, 30, 20) 0.0330 1.40×105 0.0490 1.40×104 0.0450 0.0024 0.0140
    T=0.7 (30, 20, 15) 0.0440 3.80×104 0.0550 2.20×104 0.0510 0.0021 0.0240
    (40, 20, 15) 0.0550 4.20×105 0.0770 1.10×104 0.0720 0.0024 0.0340
    (60, 30, 20) 0.0330 4.90×104 0.0410 3.50×104 0.0390 0.0018 0.0190
    T=1.5 (30, 20, 15) 0.0460 2.50×104 0.0570 1.10×104 0.0540 0.0021 0.0280
    (40, 20, 15) 0.0670 4.20×104 0.0920 2.80×104 0.0850 0.0020 0.0450
    (60, 30, 20) 0.0280 1.30×104 0.0370 1.10×105 0.0350 0.0023 0.0160
    SchIII T=0.3 (30, 20, 15) 0.0640 3.40×104 0.0920 4.90×104 0.0840 0.0028 0.0350
    (40, 20, 15) 0.1100 3.40×104 0.2000 1.80×104 0.1600 0.0021 0.0860
    (60, 30, 20) 0.0460 3.90×104 0.0700 2.40×104 0.0650 0.0020 0.0340
    T=0.7 (30, 20, 15) 0.0560 1.30×104 0.0770 1.10×105 0.0710 0.0024 0.0370
    (40, 20, 15) 0.0970 2.90×104 0.1700 1.40×104 0.1400 0.0023 0.0740
    (60, 30, 20) 0.0460 3.60×104 0.0680 2.10×104 0.0640 0.0021 0.0330
    T=1.5 (30, 20, 15) 0.0600 1.10×104 0.0830 4.20×105 0.0760 0.0024 0.0410
    (40, 20, 15) 0.1100 8.40×105 0.1800 7.00×105 0.1500 0.0024 0.0810
    (60, 30, 20) 0.0500 5.70×104 0.0730 4.20×104 0.0680 0.0018 0.0370

     | Show Table
    DownLoad: CSV

    3. From Tables 710 in the appendix, the AL of confidence intervals decreases as T increases, and the credible intervals perform well compared to the asymptotic confidence intervals. Finally, in all cases AL of the confidence intervals, the 95% intervals are larger than the 90% intervals.

    Table 7.  The AL of 90% and 95% confidence intervals and corresponding CP for ˆλML and ˆλB based on the different censoring schemes.
    ˆλB
    ˆλML IP NIP
    90% 95% 90% 95% 90% 95%
    T (n,m,k) AL CP AL CP AL CP AL CP AL CP AL CP
    Sch.I
    T=0.3 (30, 20, 15) 2.733 0.918 3.161 0.950 0.911 0.940 1.078 0.965 2.683 0.863 3.138 0.928
    (40, 20, 15) 2.871 0.930 3.309 0.945 0.828 0.947 0.986 0.970 2.810 0.879 3.317 0.925
    (60, 30, 20) 2.135 0.907 2.544 0.941 0.769 0.948 0.920 0.969 2.098 0.867 2.511 0.922
    T=0.7 (30, 20, 15) 1.665 0.873 1.935 0.943 0.741 0.934 0.877 0.965 1.614 0.851 1.864 0.927
    (40, 20, 15) 2.012 0.924 2.417 0.935 0.674 0.945 0.803 0.964 1.956 0.877 2.360 0.892
    (60, 30, 20) 1.393 0.878 1.638 0.946 0.623 0.931 0.737 0.969 1.355 0.856 1.596 0.918
    T=1.5 (30, 20, 15) 1.420 0.901 1.692 0.942 0.658 0.945 0.780 0.965 1.378 0.871 1.634 0.927
    (40, 20, 15) 1.748 0.931 2.067 0.945 0.602 0.946 0.708 0.965 1.707 0.864 2.015 0.907
    (60, 30, 20) 1.208 0.907 1.461 0.940 0.554 0.937 0.656 0.965 1.173 0.889 1.420 0.913
    Sch.II
    T=0.3 (30, 20, 15) 2.727 0.908 3.181 0.940 0.909 0.930 1.079 0.965 2.653 0.858 3.143 0.912
    (40, 20, 15) 2.917 0.920 3.260 0.937 0.824 0.955 0.972 0.965 2.883 0.867 3.243 0.923
    (60, 30, 20) 2.098 0.899 2.499 0.930 0.766 0.946 0.908 0.968 2.047 0.865 2.456 0.907
    T=0.7 (30, 20, 15) 1.648 0.886 1.984 0.942 0.738 0.944 0.876 0.961 1.592 0.858 1.930 0.917
    (40, 20, 15) 2.328 0.905 2.408 0.943 0.673 0.944 0.795 0.964 2.296 0.848 2.355 0.913
    (60, 30, 20) 1.367 0.901 1.661 0.941 0.616 0.947 0.734 0.970 1.334 0.875 1.612 0.913
    T=1.5 (30, 20, 15) 1.481 0.879 1.726 0.935 0.654 0.934 0.782 0.959 1.455 0.858 1.683 0.907
    (40, 20, 15) 1.866 0.938 2.224 0.951 0.596 0.948 0.710 0.966 1.811 0.863 2.189 0.922
    (60, 30, 20) 1.203 0.900 1.442 0.946 0.547 0.945 0.653 0.965 1.169 0.881 1.407 0.913
    Sch.III
    T=0.3 (30, 20, 15) 2.425 0.915 3.181 0.940 0.887 0.927 1.079 0.965 2.382 0.879 3.143 0.912
    (40, 20, 15) 3.676 0.928 4.329 0.951 0.798 0.948 0.945 0.974 3.932 0.857 4.748 0.912
    (60, 30, 20) 2.083 0.913 2.451 0.945 0.742 0.951 0.875 0.964 2.057 0.854 2.459 0.911
    T=0.7 (30, 20, 15) 1.771 0.919 2.142 0.949 0.721 0.940 0.855 0.966 1.727 0.866 2.120 0.920
    (40, 20, 15) 3.077 0.924 3.378 0.952 0.656 0.942 0.773 0.968 3.272 0.844 3.600 0.916
    (60, 30, 20) 1.670 0.913 1.993 0.949 0.601 0.949 0.715 0.967 1.669 0.859 1.986 0.917
    T=1.5 (30, 20, 15) 1.544 0.924 1.920 0.951 0.644 0.925 0.762 0.970 1.512 0.886 1.913 0.907
    (40, 20, 15) 2.793 0.927 3.096 0.943 0.580 0.948 0.685 0.967 2.910 0.837 3.291 0.896
    (60, 30, 20) 1.517 0.913 1.792 0.955 0.534 0.937 0.634 0.957 1.502 0.844 1.792 0.917

     | Show Table
    DownLoad: CSV
    Table 8.  The AL of 90% and 95% confidence intervals and corresponding CP for ˆμML and ˆμB based on the different censoring schemes.
    Bayesian
    ˆμML IP NIP
    90% 95% 90% 95% 90% 95%
    T (n,m,k) AL CP AL CP AL CP AL CP AL CP AL CP
    Sch.I
    T=0.3 (30, 20, 15) 0.933 0.901 1.101 0.983 0.456 0.955 0.541 0.989 0.910 0.891 1.055 0.961
    (40, 20, 15) 0.833 0.904 0.979 0.968 0.393 0.940 0.466 0.991 0.804 0.876 0.937 0.951
    (60, 30, 20) 0.710 0.915 0.837 0.963 0.366 0.952 0.427 0.987 0.695 0.890 0.805 0.931
    T=0.7 (30, 20, 15) 0.726 0.917 0.855 0.962 0.423 0.963 0.496 0.984 0.706 0.898 0.819 0.942
    (40, 20, 15) 0.688 0.916 0.814 0.960 0.364 0.957 0.432 0.990 0.671 0.896 0.783 0.931
    (60, 30, 20) 0.556 0.895 0.661 0.945 0.335 0.939 0.396 0.986 0.542 0.882 0.642 0.927
    T=1.5 (30, 20, 15) 0.645 0.918 0.766 0.959 0.387 0.952 0.457 0.983 0.632 0.901 0.739 0.938
    (40, 20, 15) 0.614 0.928 0.735 0.966 0.331 0.954 0.393 0.970 0.594 0.893 0.707 0.930
    (60, 30, 20) 0.500 0.917 0.599 0.949 0.306 0.954 0.363 0.987 0.488 0.899 0.578 0.927
    Sch.II
    T=0.3 (30, 20, 15) 0.931 0.908 1.106 0.973 0.455 0.955 0.537 0.990 0.900 0.893 1.061 0.935
    (40, 20, 15) 0.820 0.905 0.971 0.971 0.388 0.955 0.462 0.983 0.797 0.882 0.929 0.949
    (60, 30, 20) 0.700 0.918 0.834 0.975 0.362 0.962 0.426 0.982 0.681 0.905 0.798 0.949
    T=0.7 (30, 20, 15) 0.719 0.912 0.858 0.972 0.417 0.958 0.494 0.991 0.703 0.888 0.834 0.952
    (40, 20, 15) 0.757 0.918 0.816 0.970 0.358 0.957 0.423 0.985 0.735 0.899 0.785 0.956
    (60, 30, 20) 0.555 0.907 0.662 0.969 0.334 0.960 0.391 0.983 0.545 0.879 0.637 0.947
    T=1.5 (30, 20, 15) 0.654 0.909 0.768 0.966 0.384 0.952 0.456 0.984 0.640 0.874 0.744 0.933
    (40, 20, 15) 0.633 0.907 0.751 0.971 0.331 0.960 0.388 0.980 0.615 0.874 0.721 0.954
    (60, 30, 20) 0.506 0.890 0.593 0.971 0.307 0.939 0.357 0.988 0.490 0.872 0.578 0.953
    Sch.III
    T=0.3 (30, 20, 15) 0.915 0.926 1.106 0.973 0.447 0.941 0.537 0.990 0.891 0.891 1.061 0.935
    (40, 20, 15) 0.918 0.906 1.080 0.970 0.377 0.942 0.445 0.987 0.884 0.862 1.031 0.937
    (60, 30, 20) 0.693 0.925 0.832 0.972 0.351 0.960 0.417 0.990 0.675 0.900 0.801 0.934
    T=0.7 (30, 20, 15) 0.772 0.922 0.914 0.980 0.415 0.955 0.485 0.997 0.750 0.902 0.884 0.964
    (40, 20, 15) 0.834 0.925 0.990 0.974 0.345 0.950 0.411 0.987 0.806 0.876 0.941 0.935
    (60, 30, 20) 0.641 0.919 0.760 0.968 0.326 0.955 0.383 0.992 0.623 0.890 0.729 0.947
    T=1.5 (30, 20, 15) 0.704 0.921 0.842 0.971 0.382 0.942 0.446 0.992 0.686 0.896 0.808 0.947
    (40, 20, 15) 0.773 0.914 0.911 0.963 0.318 0.956 0.377 0.979 0.739 0.878 0.860 0.923
    (60, 30, 20) 0.589 0.928 0.702 0.970 0.297 0.949 0.354 0.987 0.573 0.904 0.677 0.940

     | Show Table
    DownLoad: CSV
    Table 9.  The AL of 90% and 95% confidence intervals and corresponding CP for ^S(t)ML and ^S(t)B based on the different censoring schemes.
    ^S(t)B
    ^S(t)ML IP NIP
    90% 95% 90% 95% 90% 95%
    T (n,m,k) AL CP AL CP AL CP AL CP AL CP AL CP
    Sch.I
    T=0.3 (30, 20, 15) 0.088 0.736 0.110 0.797 0.021 0.980 0.026 0.985 0.138 0.922 0.185 0.949
    (40, 20, 15) 0.113 0.771 0.140 0.813 0.022 0.987 0.026 0.993 0.164 0.919 0.215 0.948
    (60, 30, 20) 0.091 0.803 0.110 0.849 0.021 0.976 0.026 0.978 0.123 0.907 0.158 0.945
    T=0.7 (30, 20, 15) 0.068 0.789 0.088 0.856 0.020 0.965 0.024 0.963 0.099 0.903 0.133 0.946
    (40, 20, 15) 0.069 0.727 0.092 0.799 0.020 0.954 0.024 0.948 0.105 0.926 0.144 0.919
    (60, 30, 20) 0.057 0.812 0.069 0.875 0.019 0.980 0.023 0.985 0.075 0.914 0.097 0.929
    T=1.5 (30, 20, 15) 0.058 0.790 0.069 0.838 0.018 0.965 0.022 0.918 0.084 0.918 0.108 0.939
    (40, 20, 15) 0.066 0.758 0.083 0.809 0.018 0.954 0.022 0.985 0.098 0.909 0.132 0.934
    (60, 30, 20) 0.049 0.833 0.058 0.856 0.018 0.980 0.021 0.903 0.066 0.948 0.083 0.929
    Sch.II
    T=0.3 (30, 20, 15) 0.089 0.743 0.113 0.769 0.021 0.980 0.026 0.985 0.140 0.921 0.188 0.943
    (40, 20, 15) 0.111 0.754 0.143 0.802 0.021 0.965 0.026 0.963 0.159 0.904 0.215 0.954
    (60, 30, 20) 0.092 0.814 0.110 0.859 0.021 0.954 0.026 0.948 0.125 0.921 0.156 0.934
    T=0.7 (30, 20, 15) 0.068 0.794 0.080 0.802 0.020 0.943 0.024 0.933 0.098 0.910 0.124 0.944
    (40, 20, 15) 0.105 0.730 0.088 0.802 0.020 0.932 0.024 0.918 0.150 0.912 0.139 0.940
    (60, 30, 20) 0.055 0.821 0.066 0.836 0.019 0.980 0.023 0.985 0.074 0.913 0.094 0.930
    T=1.5 (30, 20, 15) 0.054 0.765 0.067 0.793 0.018 0.943 0.022 0.888 0.078 0.905 0.104 0.928
    (40, 20, 15) 0.063 0.735 0.073 0.781 0.018 0.932 0.022 0.985 0.096 0.895 0.123 0.950
    (60, 30, 20) 0.048 0.827 0.059 0.884 0.018 0.980 0.021 0.873 0.064 0.913 0.085 0.934
    Sch.III
    T=0.3 (30, 20, 15) 0.101 0.782 0.113 0.769 0.021 0.979 0.026 0.985 0.144 0.919 0.188 0.943
    (40, 20, 15) 0.089 0.668 0.114 0.730 0.021 0.943 0.026 0.933 0.132 0.888 0.180 0.926
    (60, 30, 20) 0.070 0.778 0.085 0.808 0.021 0.932 0.025 0.918 0.093 0.901 0.120 0.936
    T=0.7 (30, 20, 15) 0.065 0.766 0.074 0.815 0.020 0.921 0.024 0.903 0.093 0.908 0.119 0.951
    (40, 20, 15) 0.088 0.684 0.105 0.758 0.020 0.910 0.024 0.888 0.129 0.891 0.170 0.933
    (60, 30, 20) 0.063 0.803 0.074 0.830 0.019 0.980 0.023 0.985 0.083 0.906 0.107 0.937
    T=1.5 (30, 20, 15) 0.058 0.788 0.069 0.797 0.018 0.921 0.022 0.858 0.084 0.947 0.109 0.941
    (40, 20, 15) 0.078 0.684 0.099 0.747 0.018 0.910 0.023 0.985 0.116 0.883 0.158 0.927
    (60, 30, 20) 0.057 0.787 0.069 0.803 0.018 0.980 0.022 0.903 0.077 0.899 0.098 0.939

     | Show Table
    DownLoad: CSV
    Table 10.  The AL of 90% and 95% confidence intervals and corresponding CP for ^H(t)ML and ^H(t)B based on the different censoring schemes.
    ^H(t)B
    ^H(t)ML IP NIP
    90% 95% 90% 95% 90% 95%
    T (n,m,k) AL CP AL CP AL CP AL CP AL CP AL CP
    Sch.I
    T=0.3 (30, 20, 15) 0.472 0.716 0.537 0.769 0.078 0.961 0.093 0.966 0.475 0.943 0.556 0.963
    (40, 20, 15) 0.473 0.750 0.533 0.784 0.078 0.980 0.092 1.000 0.474 0.933 0.559 0.956
    (60, 30, 20) 0.344 0.781 0.408 0.819 0.078 1.000 0.091 1.000 0.345 0.922 0.416 0.959
    T=0.7 (30, 20, 15) 0.310 0.767 0.354 0.825 0.074 1.031 0.087 1.000 0.300 0.924 0.343 0.953
    (40, 20, 15) 0.344 0.707 0.417 0.770 0.067 0.963 0.080 0.955 0.339 0.946 0.417 0.925
    (60, 30, 20) 0.256 0.790 0.301 0.843 0.072 1.000 0.086 1.000 0.249 0.926 0.294 0.937
    T=1.5 (30, 20, 15) 0.288 0.768 0.343 0.808 0.072 1.000 0.085 1.000 0.280 0.931 0.332 0.938
    (40, 20, 15) 0.332 0.737 0.397 0.780 0.067 0.975 0.079 0.995 0.330 0.930 0.395 0.942
    (60, 30, 20) 0.243 0.810 0.296 0.825 0.071 1.000 0.084 1.000 0.235 0.959 0.290 0.931
    Sch.II
    T=0.3 (30, 20, 15) 0.470 0.722 0.546 0.742 0.078 0.927 0.093 0.975 0.466 0.936 0.562 0.949
    (40, 20, 15) 0.485 0.733 0.527 0.773 0.078 0.967 0.092 0.989 0.494 0.924 0.547 0.955
    (60, 30, 20) 0.333 0.792 0.398 0.828 0.077 1.035 0.091 1.000 0.329 0.937 0.401 0.945
    T=0.7 (30, 20, 15) 0.310 0.773 0.375 0.773 0.074 0.967 0.088 1.000 0.299 0.925 0.369 0.955
    (40, 20, 15) 0.429 0.710 0.438 0.773 0.074 0.967 0.087 0.959 0.434 0.935 0.440 0.949
    (60, 30, 20) 0.253 0.798 0.308 0.806 0.073 1.007 0.086 1.000 0.247 0.926 0.300 0.940
    T=1.5 (30, 20, 15) 0.315 0.744 0.357 0.765 0.072 0.956 0.085 1.000 0.314 0.925 0.350 0.935
    (40, 20, 15) 0.387 0.715 0.455 0.753 0.073 0.941 0.086 0.965 0.380 0.926 0.461 0.961
    (60, 30, 20) 0.248 0.805 0.290 0.852 0.071 1.000 0.084 1.000 0.239 0.925 0.285 0.941
    Sch.III
    T=0.3 (30, 20, 15) 0.417 0.761 0.546 0.742 0.078 0.927 0.093 1.000 0.420 0.935 0.562 0.949
    (40, 20, 15) 0.663 0.649 0.779 0.704 0.078 0.880 0.093 0.877 0.771 0.906 0.944 0.933
    (60, 30, 20) 0.348 0.756 0.412 0.779 0.077 0.973 0.091 1.000 0.349 0.917 0.427 0.948
    T=0.7 (30, 20, 15) 0.362 0.745 0.429 0.786 0.074 0.983 0.088 1.000 0.358 0.930 0.437 0.962
    (40, 20, 15) 0.607 0.666 0.665 0.731 0.075 0.914 0.089 0.898 0.695 0.912 0.758 0.946
    (60, 30, 20) 0.332 0.781 0.394 0.800 0.074 1.000 0.087 1.000 0.338 0.923 0.405 0.952
    T=1.5 (30, 20, 15) 0.338 0.766 0.429 0.769 0.073 0.961 0.086 1.000 0.335 0.962 0.443 0.953
    (40, 20, 15) 0.621 0.666 0.689 0.720 0.073 0.900 0.087 0.898 0.686 0.903 0.796 0.936
    (60, 30, 20) 0.331 0.765 0.394 0.774 0.072 0.968 0.086 1.000 0.333 0.923 0.408 0.950

     | Show Table
    DownLoad: CSV

    This work is supported by Researchers Supporting Project number (RSP-2021/323), King Saud University, Riyadh, Saudi Arabia.

    We are grateful to the referees and the editor for their careful reading and their constructive comments, which leads to this greatly improved paper.

    The authors acknowledge financial support from the Researchers Supporting Project number (RSP-2021/323), King Saud University, Riyadh, Saudi Arabia.

    The authors declare there is no conflict of interest.



    [1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012, CA Cancer J. Clin., 65 (2015), 87-108. doi: 10.3322/caac.21262.
    [2] W. J. Kim, S. C. Bae, Molecular biomarkers in urothelial bladder cancer, Cancer Sci., 99 (2008), 646-652. doi: 10.1111/j.1349-7006.2008.00735.x. doi: 10.1111/j.1349-7006.2008.00735.x
    [3] R. L. Siegel, K. D. Miller, A. Jemal, Cancer statistics, 2016, CA Cancer J. Clin., 66 (2016), 7-30. doi: 10.3322/caac.21332.
    [4] D. Tolomeo, A. Agostini, G. Visci, D. Traversa, C. T. Storlazzi, PVT1: A long non-coding RNA recurrently involved in neoplasia-associated fusion transcripts, Gene, 779 (2021), 145497. doi: 10.1016/j.gene.2021.145497.
    [5] Y. Y. Tseng, B. S. Moriarity, W. Gong, R. Akiyama, A. Tiwari, H. Kawakami, et al., PVT1 dependence in cancer with MYC copy-number increase, Nature, 512 (2014), 82-86. doi: 10.1038/nature13311.
    [6] Y. Kikuchi, S. Tokita, T. Hirama, V. Kochin, M. Nakatsugawa, T. Shinkawa, et al., CD8+ T-cell immune surveillance against a tumor antigen encoded by the oncogenic long non-coding RNA, PVT1, Cancer Immunol. Res., 9 (2021), 1342-1353. doi: 10.1158/2326-6066.CIR-20-0964.
    [7] E. Tesfaye, E. Martinez-Terroba, J. Bendor, L. Winkler, C. Olivero, K. Chen, et al., The p53 transcriptional response across tumor types reveals core and senescence-specific signatures modulated by long noncoding RNAs, Proc. Natl. Acad. Sci. USA, 118 (2021). doi: 10.1073/pnas.2025539118.
    [8] K. Shigeyasu, S. Toden, T. Ozawa, T. Matsuyama, T. Nagasaka, T. Ishikawa, et al., The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer, Mol. Cancer, 19 (2020), 155. doi: 10.1186/s12943-020-01277-4.
    [9] Z. Liu, H. Zhang, LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma, Mol. Cancer, 8 (2017), 64273-64282. doi: 10.18632/oncotarget.19604. doi: 10.18632/oncotarget.19604
    [10] Y. Wang, J. Zhou, Z. Wang, P. Wang, S. Li, Upregulation of SOX2 activated LncRNA PVT1 expression promotes breast cancer cell growth and invasion, Biochem. Bioph. Res. Commun., 493 (2017), 429-436. doi: 10.1016/j.bbrc.2017.09.005. doi: 10.1016/j.bbrc.2017.09.005
    [11] M. Iden, S. Fye, K. Li, T. Chowdhury, R. Ramchandran, J. S. Rader, The lncRNA PVT1 contributes to the cervical cancer phenotype and associates with poor patient prognosis, PLoS One, 11 (2016), e0156274. doi: 10.1371/journal.pone.0156274.
    [12] X. Yu, J. Zhao, Y. He, Long non-coding RNA PVT1 functions as an oncogene in human colon cancer through miR-30d-5p/RUNX2 axis, J BUON, 23 (2018), 48-54.
    [13] Y. R. Yang, S. Z. Zang, C. L. Zhong, Y. X. Li, S. S. Zhao, X. J. Feng, Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer, Int. J. Clin. Exp. Pathol, 7 (2014), 6929-6935.
    [14] Y. Wu, W. Gu, X. Han, Z. Jin, LncRNA PVT1 promotes the progression of ovarian cancer by activating TGF-beta pathway via miR-148a-3p/AGO1 axis, J. Cell Mol. Med., (2021). doi: 10.1111/jcmm.16700.
    [15] J. Yang, C. Li, A. Mudd, X. Gu, LncRNA PVT1 predicts prognosis and regulates tumor growth in prostate cancer, Biosci. Biotech. Bioch., 81 (2017), 2301-2306. doi: 10.1080/09168451.2017.1387048. doi: 10.1080/09168451.2017.1387048
    [16] M. Izadifard, H. Pashaiefar, M. Yaghmaie, M. Montazeri, M. Sadraie, M. Momeny, et al., Expression analysis of PVT1, CCDC26, and CCAT1 long noncoding RNAs in acute myeloid leukemia patients, Genet. Test. Mol. Bioma., 22 (2018), 593-598. doi: 10.1089/gtmb.2018.0143.
    [17] A. Abbate, D. Tolomeo, I. Cifola, M. Severgnini, A. Turchiano, B. Augello, et al., MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences, Leukemia, 32 (2018), 2152-2166. doi: 10.1038/s41375-018-0033-0.
    [18] N. Yazdi, M. Houshmand, A. Atashi, A. Kazemi, A. A. Najmedini, M. N. Zarif, Long noncoding RNA PVT1: potential oncogene in the development of acute lymphoblastic leukemia, Turk. J. Biol., 42 (2018), 405-413. doi: 10.3906/biy-1801-46. doi: 10.3906/biy-1801-46
    [19] H. Handa, K. Honma, T. Oda, N. Kobayashi, Y. Kuroda, K. Kimura-Masuda, et al., Long Noncoding RNA PVT1 Is Regulated by Bromodomain Protein BRD4 in Multiple Myeloma and Is Associated with Disease Progression, Int. J. Mol. Sci., 21 (2020). doi: 10.3390/ijms21197121.
    [20] A. C. Panda, I. Grammatikakis, K. M. Kim, S. De, J. L. Martindale, R. Munk, et al., Identification of senescence-associated circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1, Nucleic Acids Res., 45 (2017), 4021-4035. doi: 10.1093/nar/gkw1201.
    [21] L. Wan, M. Sun, G. J. Liu, C. C. Wei, E. B. Zhang, R. Kong, et al., Long noncoding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating lats2 expression, Mol. Cancer Ther., 15 (2016), 1082-1094. doi: 10.1158/1535-7163.MCT-15-0707.
    [22] C. Zeng, X. Yu, J. Lai, L. Yang, S. Chen, Y. Li, Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia, J. Hematol. Oncol., 8 (2015), 126. doi: 10.1186/s13045-015-0223-4.
    [23] D. Guo, Y. Wang, K. Ren, X. Han, Knockdown of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 expression, Exp. Cell Res., 362 (2018), 172-179. doi: 10.1016/j.yexcr.2017.11.014. doi: 10.1016/j.yexcr.2017.11.014
    [24] G. Ping, W. Xiong, L. Zhang, Y. Li, Y. Zhang, Y. Zhao, Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer, Am. J. Transl. Res., 10 (2018), 138-149.
    [25] X. Z. Wu, H. P. Cui, H. J. Lv, L. Feng, Knockdown of lncRNA PVT1 inhibits retinoblastoma progression by sponging miR-488-3p, Biomed. Pharmacother., 112 (2019), 108627. doi: 10.1016/j.biopha.2019.108627.
    [26] Y. Cai, J. Wan, Competing endogenous RNA regulations in neurodegenerative disorders: current challenges and emerging insights, Front. Mol. Neurosci., 11 (2018), 370. doi: 10.3389/fnmol.2018.00370.
    [27] X. Qi, D. H. Zhang, N. Wu, J. H. Xiao, X. Wang, W. Ma, ceRNA in cancer: possible functions and clinical implications, J. Med. Genet., 52 (2015), 710-718. doi: 10.1136/jmedgenet-2015-103334. doi: 10.1136/jmedgenet-2015-103334
    [28] M. Chen, R. Zhang, L. Lu, J. Du, C. Chen, K. Ding, et al., LncRNA PVT1 accelerates malignant phenotypes of bladder cancer cells by modulating miR-194-5p/BCLAF1 axis as a ceRNA, Aging (Albany NY), 12 (2020), 22291-22312. doi: 10.18632/aging.202203.
    [29] C. Yu, L. Liu, W. Long, Z. Feng, J. Chen, L. Chao, et al., LncRNA PVT1 regulates VEGFC through inhibiting miR-128 in bladder cancer cells, J. Cell Physiol., 234 (2019), 1346-1353. doi: 10.1002/jcp.26929.
    [30] V. Karantza, Keratins in health and cancer: more than mere epithelial cell markers, Oncogene, 30 (2011), 127-138. doi: 10.1038/onc.2010.456. doi: 10.1038/onc.2010.456
    [31] P. A. Coulombe, M. B. O mary, 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments, Curr. Opin. Cell Biol., 14 (2002), 110-122.
    [32] R. Moll, M. Divo, L. Langbein, The human keratins: biology and pathology, Histochem. Cell Biol., 129 (2008), 705-733. doi: 10.1007/s00418-008-0435-6. doi: 10.1007/s00418-008-0435-6
    [33] J. I. Epstein, An update of the Gleason grading system, J. Urol., 183 (2010), 433-440. doi: 10.1016/j.juro.2009.10.046. doi: 10.1016/j.juro.2009.10.046
    [34] S. Liu, R. M. Cadaneanu, B. Zhang, L. Huo, K. Lai, X. Li, et al., Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone, PLoS One, 11 (2016), e0163232. doi: 10.1371/journal.pone.0163232.
    [35] S. Bundela, A. Sharma, P. S. Bisen, Potential therapeutic targets for oral cancer: ADM, TP53, EGFR, LYN, CTLA4, SKIL, CTGF, CD70, PLoS One, 9 (2014), e102610. doi: 10.1371/journal.pone.0102610.
    [36] J. A. Sharp, S. L. Mailer, P. C. Thomson, C. Lefevre, K. R. Nicholas, Identification and transcript analysis of a novel wallaby (Macropus eugenii) basal-like breast cancer cell line, Mol. Cancer, 7 (2008), 1. doi: 10.1186/1476-4598-7-1.
    [37] L. Lima, M. Neves, M. I. Oliveira, L. Dieguez, R. Freitas, R. Azevedo, et al., Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases, Urol. Oncol., 35 (2017), 675 e1-675 e8. doi: 10.1016/j.urolonc.2017.08.012.
    [38] M. Eckstein, R. M. Wirtz, M. Gross-Weege, J. Breyer, W. Otto, R. Stoehr, et al., mRNA-expression of KRT5 and KRT20 defines distinct prognostic subgroups of muscle-invasive urothelial bladder cancer correlating with histological variants, Int. J. Mol. Sci., 19 (2018). doi: 10.3390/ijms19113396.
    [39] S. W. Cho, J. Xu, R. Sun, M. R. Mumbach, A. C. Carter, Y. G. Chen, et al., Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element, Cell, 173 (2018), 1398-1412. doi: 10.1016/j.cell.2018.03.068.
    [40] Y. Wang, C. E. Kaiser, B. Frett, H. Y. Li, Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators, J. Med. Chem., 56 (2013), 5219-5230. doi: 10.1021/jm3017706. doi: 10.1021/jm3017706
    [41] S. A. Kerk, T. Papagiannakopoulos, Y. M. Shah, C. A. Lyssiotis, Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment, Nat. Rev. Cancer, 21 (2021), 510-525. doi: 10.1038/s41568-021-00375-9. doi: 10.1038/s41568-021-00375-9
    [42] J. Huang, Current developments of targeting the p53 signaling pathway for cancer treatment, Pharmacol. Ther., 220 (2021), 107720. doi: 10.1016/j.pharmthera.2020.107720.
    [43] A. Kamoun, A. de Reynies, Y. Allory, G. Sjodahl, A. G. Robertson, R. Seiler, et al., A consensus molecular classification of muscle-invasive bladder cancer, Eur. Urol., 77 (2020), 420-433. doi: 10.1016/j.eururo.2019.09.006.
    [44] M. Fraga, M. Yanez, M. Sherman, F. Llerena, M. Hernandez, G. Nourdin, et al., Immunomodulation of t helper cells by tumor microenvironment in oral cancer is associated with ccr8 expression and rapid membrane vitamin d signaling pathway, Front. Immunol., 12 (2021), 643298. doi: 10.3389/fimmu.2021.643298.
    [45] K. D. da Silva, P. C. Caldeira, A. M. Alves, A. C. U. Vasconcelos, A. P. N. Gomes, M. C. F. de Aguiar, et al., High CD3(+) lymphocytes, low CD66b(+) neutrophils, and scarce tumor budding in the invasive front of lip squamous cell carcinomas, Arch. Oral. Biol., 104 (2019), 46-51. doi: 10.1016/j.archoralbio.2019.05.027.
    [46] O. Stasikowska-Kanicka, M. Wagrowska-Danilewicz, M. Danilewicz, Immunohistochemical analysis of foxp3(+), CD4(+), CD8(+) cell infiltrates and PD-L1 in oral squamous cell carcinoma, Pathol. Oncol. Res., 24 (2018), 497-505. doi: 10.1007/s12253-017-0270-y.
    [47] Y. Wei, B. Han, W. Dai, S. Guo, C. Zhang, L. Zhao, et al., Exposure to ozone impacted Th1/Th2 imbalance of CD(4+) T cells and apoptosis of ASMCs underlying asthmatic progression by activating lncRNA PVT1-miR-15a-5p/miR-29c-3p signaling, Aging (Albany NY), 12 (2020), 25229-25255. doi: 10.18632/aging.104124.
    [48] O. Demaria, E. Vivier, Immuno-oncology beyond TILs: Unleashing TILCs, Cancer Cell, 37 (2020), 428-430. doi: 10.1016/j.ccell.2020.03.021. doi: 10.1016/j.ccell.2020.03.021
    [49] J. Fu, H. Shi, B. Wang, T. Zhan, Y. Shao, L. Ye, et al., LncRNA PVT1 links Myc to glycolytic metabolism upon CD4(+) T cell activation and Sjogren's syndrome-like autoimmune response, J. Autoimmun., 107 (2020), 102358. doi: 10.1016/j.jaut.2019.102358.
    [50] J. Vivian, A. A. Rao, F. A. Nothaft, C. Ketchum, J. Armstrong, A. Novak, et al., Toil enables reproducible, open source, big biomedical data analyses, Nat. Biotechnol., 35 (2017), 314-316. doi: 10.1038/nbt.3772.
    [51] S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data, BMC Bioinformatics, 14 (2013), 7. doi: 10.1186/1471-2105-14-7.
    [52] G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner, A. C. Obenauf, et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity, 39 (2013), 782-795. doi: 10.1016/j.immuni.2013.10.003.
    [53] J. Liu, T. Lichtenberg, K. A. Hoadley, L. M. Poisson, A. J. Lazar, A. D. Cherniack, et al., An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics, Cell, 173 (2018), 400-416. doi: 10.1016/j.cell.2018.02.052.
  • This article has been cited by:

    1. M. Nagy, Adel Fahad Alrasheedi, Behnaz Ghoraani, Estimations of Generalized Exponential Distribution Parameters Based on Type I Generalized Progressive Hybrid Censored Data, 2022, 2022, 1748-6718, 1, 10.1155/2022/8058473
    2. M. Nagy, Adel Fahad Alrasheedi, Muye Pang, Classical and Bayesian Inference Using Type-II Unified Progressive Hybrid Censored Samples for Pareto Model, 2022, 2022, 1754-2103, 1, 10.1155/2022/2073067
    3. M. Nagy, M. H. Abu-Moussa, Adel Fahad Alrasheedi, A. Rabie, Expected Bayesian estimation for exponential model based on simple step stress with Type-I hybrid censored data, 2022, 19, 1551-0018, 9773, 10.3934/mbe.2022455
    4. M. Nagy, Expected Bayesian estimation based on generalized progressive hybrid censored data for Burr-XII distribution with applications, 2024, 14, 2158-3226, 10.1063/5.0184910
    5. Magdy Nagy, Mohamed Ahmed Mosilhy, Ahmed Hamdi Mansi, Mahmoud Hamed Abu-Moussa, An Analysis of Type-I Generalized Progressive Hybrid Censoring for the One Parameter Logistic-Geometry Lifetime Distribution with Applications, 2024, 13, 2075-1680, 692, 10.3390/axioms13100692
    6. Mahmoud M. Abdelwahab, Anis Ben Ghorbal, Amal S. Hassan, Mohammed Elgarhy, Ehab M. Almetwally, Atef F. Hashem, Classical and Bayesian Inference for the Kavya–Manoharan Generalized Exponential Distribution under Generalized Progressively Hybrid Censored Data, 2023, 15, 2073-8994, 1193, 10.3390/sym15061193
  • Reader Comments
  • © 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(3359) PDF downloads(166) Cited by(1)

Figures and Tables

Figures(7)  /  Tables(3)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog